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Foreword 
As a proprietary right fostering innovation, patents play a role in a competitive 
economy.  Patents  rights  are  statutory  intellectual  property  rights  granted  by  the 
government to an inventor to manufacture, use or market an invention which in turn 
benefits  consumers  through  the  development  of  new  and  improved  products  and 
processes.  
 
The 2005 Patents [Amendment] Act marks a distinct evolution in Indian Patent 
Law. With the inauguration of the product patents regime, India is fully compliant with 
Article 65(4). The contours of the Law and Rules are yet to be defined but it is clear that 
the  Amendment  builds  on  the  Ordinance  of  March  2004  taking  into  consideration 
objections  raised  both  by  the  public  and  political  parties  alike.  The  paper  attempts  a 
comparison  of  Indian  legislative  provisions  vis-à-vis  the  minimum  standards  of 
protection required under the TRIPS Agreement and broader standards as defined in the 
Paris Convention. It attempts further to plot an evolution in the law as first promulgated 
in 1970 to that of its successive amendments.  
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1.  Introduction 
The Trade Related Aspects of Intellectual Property Rights (TRIPS) Agreement 
was the result of seven years of negotiations, from September 1986 to December 1993, as 
part of the Uruguay Round of Multilateral Trade Negotiations of the General Agreement 
on Tariffs and Trade. It was promulgated on the 1
st of January 2005 thus forming a part 
of the legal obligations of the World Trade Organization and its member countries. It 
dramatically  increased  the  minimum  standards  of  protection  for  intellectual  property 
rights,
1 including patents. The TRIPS Agreement, broadly, prescribed the following time 
line for compliance: 
 
1.  All  World  Trade  Organization  member  countries  had  1  year  (up  to  the  1
st  of 
January, 1996) to phase in the minimum standards of protection.  
2.  Developing Countries were given an additional period of 4 years (up to January 
2000) and  Least Developed Countries an additional period of 10  years (up to 
January 2006) to phase in these minimum standards of protection. 
3.  A  further  period  of  5  years  (up  to  January  2005)  was  given  to  developing 
countries to introduce a product patents regime. Meanwhile, a ‘mailbox’ facility 
starting from the 1
st of January1995 to receive product patent applications in the 
field of pharmaceuticals and agricultural-chemicals till the 31
st of December 2004 
was required for along with the provision of Exclusive Marketing Rights in lieu of 
product patents during the transition period. 
4.  Product Patents in Least Developed Countries were to be introduced by 2006, 
however the transition period was extended to the 1
st of January, 2016 by the 
Doha Declaration, paragraph 7 
 
The Indian Government has promulgated changes in its Intellectual Property Law, 
especially  patents,  to  meet  its  commitments  under  the  Trade  Related  Aspects  of 
Intellectual Property Rights Agreement. The Patents Act, 1970 (20
th April, 1972) read 
                                                 
1  Trade  Marks,  Copyrights,  Geographical  Indications,  Designs,  Industrial  Designs,  Layout  Designs  of 
Integrated Circuits 
   2 
with the Patents Rules, 1972 (20
th April, 1972), which revoked the Patents and Designs 
Act 1911, has been amended thrice to bring India in compliance with its international 
obligations under the TRIPS Agreement: 
 
1.  Patents Amendment Act, 1999 (26
th March 1999, enforced retrospectively from 
1
st January 1995) read with the Patents Rules, 1972 (20
th April, 1972)  
2.  Patents Amendment Act, 2002 (25
th June 2002, enforced on 20
th May 2003) read 
with the Patents Amendment Rules (enforced on 20
th May 2003) 
3.  The  Patents  Amendment  Ordinance,  2004  was  promulgated  into  the  Patents 
[Amendment]  Act  2005  on  the  23
rd  of  March  2005.  It  is  to  be  read  with  the 
Patents  Amendment  Rules,  2005.  The  Patents  Amendment  Ordinance  (a 
temporary executive decree not debated in the Parliament) 2004 was promulgated 
on the 26
th of December 2004 under Article 123(1) of the Constitution of India 
after receiving Presidential assent
2. The Ordinance had the same force as an Act 
of Parliament
3 and was to terminate at the expiration of six weeks from the re-
assembly of the Parliament, or before, if resolutions disapproving it were passed 
by both Houses,
4 else it could have been withdrawn by the President of India at 
any  time.
5  The  Ordinance  took  effect  as  soon  as  it  was  promulgated  by  the 
President, subject to retrospective reversal, had the Legislature passed an Act to 
the same effect.
6 The Ordinance could have been challenged on the ground of 
mala fides
7 (in bad faith).  
 
This paper attempts to catalog the successive amendments made to the Patents 
regime in India, with a view to fulfilling its international obligations under the Trade 
                                                 
2  Chapter III, Legislative Powers of the President of India, The Constitution of India, Section. 123(1): “If 
at any time, except when both houses of the parliament are in session, the president is satisfied that 
circumstances exist which render it necessary for him to take immediate action, he may promulgate such 
ordinance as the circumstances appear to him to require” (emphasis added) 
3  s. 123(2), The Constitution of India 
4  s. 123(2)(a), The constitution of India 
5  s. 123(2)(b), The constitution of India 
6  The Shorter Constitution of India (Eleventh Edition) by DD. Basu, Page 380 
7  Air 1982 SC paragraph 27 and 29   3 
Related Aspects of Intellectual Property Rights and the Paris Convention. The first half 
deals with the substantive aspects and the second with the procedural aspects of patents 
law in India. 
 
2.  Patents Legislation and International Obligations: India 
2.1.  Rights granted by the Patent: 
A Patent gives a monopoly right to a person who has invented a new and useful 
product or a new process of making a product or an improvement or modification of an 
existing  product  or  process
8.  It  is  a  statutory  grant  conferring  exclusive  right  to 
manufacture the patented product or manufacture a product according to the patented 
process for a limited period of time, that is, a period of 20 years.
9 As provided for in the 
2002 amendment and in keeping with the TRIPS Agreement, a patent confers on the 
owner the exclusive right by himself, his agents, assignees or licensees to prevent any 
third party, without explicit authorization, from making, using, offering for sale, selling 
or importing for these purposes the patented product.
10 In the case of the grant of a patent 
for  a  method  or  process  of  manufacture,  this  right  extends  to  the  ‘product  obtained 
directly by the patented process,’
11 subject to prescribed exceptions.
12  
                                                 
8  See  P.Narayanan,  Patents  Law,  3
rd  Edition,  in  respect  of  any  “improvement  in  or  modification  of” 
previous invention called the main invention as described or disclosed in the complete specification (not 
limited to the invention as claimed) for which a patent has been granted or an application has been made, 
Section 55(2), Patents Act (1970), Page 69-71 
9  Section 53(1), Patents Act, 1970: “Subject to the provisions of this act, the term of every patent granted, 
after the commencement of the Patents (Amendment) Act, 2002, and the term for every patent which has 
not expired and has not cased to have effect, on the date of such commencement, under this Act, shall be 
twenty years from the date of filling of the application for the patent” (emphasis added). This provision 
was introduced by the 2002 Amendment in conformity with Article 33, the Trade Related Aspects of the 
Intellectual Property Rights Agreement (1995). 
10 Section 48(a), the Patents Act, 1970 as amended in 2002. This is in conformity with Article 28(1)(a) the 
Trade Related Aspects of Intellectual Property Rights Agreement (1995) and goes further than the rights 
conferred under the Paris Convention, Article 5quarter. 
11 Section 48(b), the Patents act, 1970 as amended in 2002. This is in conformity with Article 28(1)(b), the 
Trade Related Aspects of Intellectual Property Rights Agreement (1995).  
12 Rights of co-owners (Section 50), Use of patents by the Government (Section 47), Powers of the Central 
Government to use of inventions for the purposes of the Government (Section 100; ), Acquisitions of 
inventions and Patents by the Central Government (Section 102), Compulsory Licenses (Sections 83 to 
94), etc   4 
 
2.2.  Time Frame for complying with the Trade related aspects of Intellectual 
property Rights Agreement:  
The Trade Related Aspects of Intellectual Property Rights Agreement provides 
for a three stage time frame for developing countries to comply with their international 
obligations:  
1.  The introduction of a ‘mailbox’ facility from the 1
st of January 1995 to receive 
pharmaceutical  and  agricultural-chemical  patent  applications  until  the  31
st  of 
December 2004 along with the grant of Exclusive Marketing Rights in countries 
which did not provide for product patents in pharmaceuticals and agricultural-




15  The  mailbox  provision  allowed  applicants  to  file  for  patents, 
thereby  establish  a  filing  date  while  at  the  same  time  deferring  to  grant 
pharmaceutical and agricultural-chemical patents. The date of filing is important 
as it is used to assess whether the patent application at the time of filing, given the 
prior art, meets the necessary conditions for establishing patentability, which are, 
novelty, utility and inventive step.
16  
                                                 
13 To the extent that developing country member is obliged by this agreement to extend product patent 
protection, it may delay the application for an additional period of 5 years.  
14 Article 70(8) Trade Related Aspects of the Intellectual Property Rights Agreement, established, that a 
contracting state  which does not  make Patent protection available from  the 1
st of January 1995, for 
pharmaceuticals and agricultural chemicals, will have to: (i) provide a means by which applications for 
patents for such inventions can be filed (ii) apply to these applications the criteria of patentability as 
established by Trade Related Aspects of the Intellectual Property Rights Agreement as if those criteria 
were applied on the date of filing or priority, (iii) provide patent protection counted from the filing date 
for patents which meet the criteria under (ii). 
15 Under article 70(9) an Exclusive Marketing Rights to sell or distribute the article or substance for the 
applicant, his agents or licensees, on and from the date of approval by the controller for a period of 5 
years or till the date of the grant of the patent or the date of rejection of the application, whichever is 
earlier. Before the Exclusive Marketing Right is so available, it has to be established that the applicant 
has, (i) filed a patent application in a World Trade Organization member country on or after the 1
st 
January, 1995 or thereafter, (ii) a patent application has been filed for the grant in another World Trade 
Organization member country after the afore date stated, (iii) marketing approval has been obtained for 
such a product in the said other World Trade Organization member, and (iv) marketing approval has been 
obtained in the host country 
16 The  effects  of  the  2005  TRIPS  implementation  deadline  on  access  to  medicines:  Médecins  Sans 
Frontières Campaign for Access to Essential Medicines, February 2005   5 
2.  All  other  provisions  under  the  Agreement  pertaining  to  patents  were  to  be 
complied  with  by  1
st  January  2000,  Article  65(2),
17  including,  the  reversal  of 
burden  of  proof  to  strengthen  ‘process  patent’  protection,
18  the  provisions  of 
compulsory licensing (license to implement a patent against the will of the patent 
owner), a twenty year term of patent protection, and  
3.  The introduction of product patents in all fields of technology was required from 
the 1
st of January 2005, Article 65(4).  
 
India chose to take advantage of the ten year transition period, provided under 
Article 65(4) of the Agreement. 
 
2.3.  Provisions under the Trade Related Aspects of Intellectual property Rights 
Agreement and Consequent Amendments in Indian Patents Law:  
2.3.1.  Objectives and principles: 
The Trade Relate Aspects of Intellectual Property Rights Agreement adopted a 
‘Paris plus’ approach under Article 2(1)
19 and provides the minimum standards for patent 
protection  in  Section  V  of  the  Agreement  (Articles  27-34).  The  ‘objectives’  and 
‘principles,’  provided  for  in  the  Agreement,  offer  an  important  framework  for  the 
interpretation and application of the provisions of the Agreement. The specific objectives 
of the Agreement are stated in Article 7,
20 which provides that national governments 
‘should’  grant  protection  and  enforcement  to  intellectual  property  rights,  that  is,  the 
promotion of technological innovation and the transfer and dissemination of technology 
                                                 
17 A developing country is entitled to delay for a further period of 4 years the date of application [(in 
addition to Article 64(1), no member shall be obliged to apply the provisions of Trade Related Aspects of 
Intellectual Property Rights before the expiry of a general period of 1 year following the date of entry 
into force of the World Trade Organization] 
18 Inserted under the 2002 Amendment, Section 104A 
19 Members shall comply with Articles 1-12, and Article 19 of the Paris Convention 1967 (last revised on 
September 28, 1979). Nothing in parts I to IV of this Agreement shall derogate from existing obligations 
that members have to each other under the Paris Convention 
20 “The protection and enforcement of Intellectual Property Rights should contribute to the promotion of 
technological  innovations  and  to  the  transfer  and  dissemination  of  technology  and  to  the  mutual 
advantage of producers and users of technological knowledge and in a manner conducive to social and 
economic welfare, and to a balance of rights and obligations”   6 
and that these objectives have to be pursued to the mutual advantage of the producers and 
users of technological knowledge, be conducive to social and economic welfare and must 
result in a balance of rights and obligations.  
 
The  principles  of  the  Agreement  are  vested  in  Article  8,  which  contains  two 
general provisions. The first, where the member states in either formulating or amending 
their laws or regulations, ‘may’ adopt measures ‘to protect’ public health and nutrition 
and to promote public interest in sectors of vital importance to their socio-economic and 
technological developments and the second to ‘prevent’ the abuse of intellectual property 
rights  or  resort  to  practices  which  unreasonably  restrain  trade  or  adversely  affect  the 
international transfer of technology. While Article 8(1)
21 empowers the member countries 
to  undertake  public  interest  benefaction,  Article  8(2)
22  enunciates  the  adoption  of 
measures to prevent the ‘abuse of intellectual property rights.’ The principle articulated in 
8(2)  is  further  substantiated  in  the  mechanisms  of  Articles  31(k)
23  and  40,
24  more 
specifically, which together, give domestic legislation an opportunity to control abuses or 
anti-competitive  practices  associated  with  the  exercise  of  intellectual  property  rights. 
Article  8  facilitates  legislating  limitations  to  exclusive  patent  rights  along  with  the 
enactment of legislative provisions concerning compulsory licensing. 
 
2.3.2.  Patentable Subject Matter: 
Article 27(1) of the Agreement provides that patents are to be available for:  
                                                 
21 “Members may, in formulating or amending their laws and regulations, adopt measures necessary to the 
protect public health and nutrition, and to promote the public interest in sectors of vital importance to 
their socio-economic and technological development, provided that such measures are consistent with the 
provisions of this agreement” Article 8(1) 
22 “Appropriate measures, provided that they are consistent with the provisions of the Agreement, may be 
needed to prevent the abuse of Intellectual property rights by right holders or the resort to practices that 
unreasonably restrain trade or adversely affect the international transfer of technology, Article 8(2) 
23 Given the conditions for the grant of a compulsory license, a member is not required to “[] make efforts 
to obtain authorization from the right holder on reasonable commercial terms and conditions and such 
efforts have not been successful within a reasonable period of time” and compulsory licenses granted are 
not required “[to] be authorized predominantly for the supply of the domestic market of the member 
authorizing such use.” Further, the need to correct anti-competitive practices may be taken into account 
in determining the amount of remuneration in such case. 
24 Control of Anti-Competitive Practices in Contractual Licenses 
   7 
(i)  both product and process inventions,  
(ii)  in all fields of technology,  
(iii)  provided they are new, involve an inventive step and capable of industrial 
application.  
(iv)  footnote  5  of  the  agreement  provides  that  for  these  purposes  the  term 
‘inventive step’ and ‘capable of industrial application’ may be deemed to be 
synonymous with the terms ‘non-obvious’ and ‘useful’ respectively. 
(v)  patent  are  to  be  made  available  and  patent  rights  enjoyable  without 
discrimination
25 as to (a) place of invention, the (b) field of technology and (c) 
whether products are imported
26 or locally produced.  
 
Exclusions to Article 27(1): 
 
(i)  Article 27(2) provides for exclusions from patentability of inventions which 
are ‘necessary’ to protect ordre public or morality
27  
                                                 
25 In  Canada  –  Patent  Protection  of  pharmaceutical  patents  (WT/DS114/R:  17  March  2000),  it  was 
established that “discrimination may arise from explicitly different treatment, sometimes called ‘de jure 
discrimination’, but it may also arise from ostensibly identical treatment which, due to differences in 
circumstances, produce differentially disadvantageous effects, sometimes called ‘de facto discrimination’ 
[which] is a general term describing the legal conclusion that an ostensibly neutral measure transgresses a 
non-discrimination  norm  because  its  (i)  actual  effect  is  to  impose  differentially  disadvantageous 
consequences on certain parties, and (ii) because those differential effects are found to be wrong or 
unjustifiable” 
26 Article 5A (1) of the Paris Convention prohibits the mere act of importation of patented articles by the 
patentee from any other member country as constituting the basis for forfeiture of the patent. However, 
Article 5A(2) further lays down that each Paris member is free to provide for the grant of compulsory 
license to prevent patent abuse, such as failure to work the patent in the country of grant. Given this, in 
Intellectual Property Rights and International Trade, edited by Carlos Correa and A.Yusuf, it is held 
that, “The relationship between 5A of the Paris Convention and Article 27(1) is not clear, as the former 
authorizes the granting of compulsory licenses on the basis of failure to work, while article 27(1) is 
intended, at least in principle, to restrict compulsory licenses on such grounds,” Page 191 
27 Patent Rights by Carlos Correa in Intellectual Property and International Trade edited by Carlos Correa 
and A.Yusuf, “[] the concept of ordre public [] may be interpreted as being narrower that ‘public order’ 
or ‘public interest.’ [There is] no generally accepted notion of ordre public: member countries have 
therefore a certain degree of flexibility to define which hypotheses are covered, depending on their own 
conception of the protection of public values. Article 27(2), itself indicates that the concept is not limited 
to ‘security’ reasons; it also relates to the protection of ‘human, animals or plant life or health’ and may 
be  applied  to  inventions  that  may  lead  to  ‘serious  prejudice  to  the  environment’.”  Also  see  India, 
IP/C/M/28, para. 127   8 
(ii)  including to protect human, animal or plant life or health or to avoid serious 
prejudice  to  the  environment,  provided  that  such  exclusions  are  not  made 
merely because the exploitation is prohibited under domestic law
28.  
(iii)  Article 27(3) further excludes from patentability  
(a) diagnostic, therapeutic and surgical methods for the treatment of humans 
and animals, 
(b) plants and animals other than micro-organisms and essentially biological 
processes for the production of plants or animals other than non-biological 
and micro-biological processes.  
Members  are  also  required  to  provide  for  the  protection  of  plant  varieties 
either by patents or by an effective sui generis system or any combination 
thereof (Protection of Plant Varieties and Farmers Rights Act, 2001). 
 
The  TRIPs  Agreement  does  not  define  what  constitutes  an  invention:  it  only 
specifies the requirements to be satisfied in order to obtain protection for an invention. 
Novelty, non-obviousness (inventive step) and utility (industrial applicability) determine 
the  criteria  of  patentability.  Novelty  provides  a  proper  incentive  for  innovation, 
rewarding  that  which  is  new  and  not  imitative.
29  Non-obviousness  establishes  a 
patentability step, a level of development beyond the prior art that must be accomplished, 
before a patent can be issued, it is a ‘non-triviality’ requirement.
30 The requirement that a 
claim be ‘capable of industrial application’ tends to exclude areas of basic research from 
patentability. A disclosure requirement is provided for under Article 29 of the Agreement 
which requires a patent applicant to disclose the invention in a manner sufficiently clear 
and complete for it to be executed by a person skilled in the art. It may also require the 
applicant to indicate the ‘best mode’ required for carrying out the invention known to the 
inventor  at  the  date  of  filing  of  the  patent  application  or  the  date  of  priority.  The 
                                                 
28 Article 4 quarter of the Paris Convention, lays down the principle that the grant of a patent cannot be 
refused or invalidated on the ground that the sale of the patented product (or of a product resulting from 
the patented process) is restricted or limited by domestic law 
29 Report by the USPTO (2003), To promote innovation: The proper balance of competition and patent law 
and policy, Chapter 4, page 2 
30 id   9 
disclosure  requirement  guarantees  a  relatively  swift  dissemination  of  technical 
information from which others in the art can learn.  
 
As patents are granted under national laws and have territorial application the 
specific ‘scope’ of patentability has not been negotiated at the TRIPS Council.
31 The 
‘level’ of protection is crafted in the national domain.
32 India expressed the view that the 
lack of clear definitions for the ‘criteria’ of patentability has left grey areas, in particular 
with  respect  to  the  [threshold]  definition  of  the  term  ‘invention’  and  the  ‘scope’  of 
patentable  micro-organisms  and  microbiological  and  non-biological  processes.
33  This 
may result in poor quality or questionable patents which are likely invalid or contain 
claims that are overly broad.
34 Another concern that has plagued India with respect to the 
TRIPS  Agreement  is  the  patenting  of  products  based  on  India’s  bio-diversity  and 
traditional knowledge (bio-piracy)
35 without recognizing and rewarding the traditional 
contribution of rural communities to the conservation of biological diversity. This brings 
into purview the issue of compatibility between the TRIPS Agreement and the principles 
of Convention on Biological Diversity which reaffirms the sovereign rights of the States 
                                                 
31 India, IP/C/M/28 
32 id 
33 India, IP/C/W/161; IP/C/M/28 para. 128 
34 Report by the USPTO (2003), To promote innovation: The proper balance of competition and patent law 
and policy, Introduction, page 5 
35 As the Trade Related Aspects of Intellectual Property Rights Agreement contains no provisions allowing 
a members claim to enforce ‘fair and equitable sharing of benefits’ from the patenting of its own genetic 
resources abroad, in IP/C/W/429/Rev.1, on 27
th September, 2004 Brazil, Cuba, Ecuador, India, Pakistan, 
Peru, Thailand and Venezuela proposed to implement a legally binding obligation to (i) disclose the 
source and country of origin of biological resources and/or traditional knowledge used in the invention, 
(ii)  provide  evidence  of  prior  informed  consent  through  approval  of  authorities  under  the  relevant 
national  regimes,  and  (iii)  provide  evidence  of  fair  and  equitable  benefit  sharing  under  the  relevant 
national regimes. This will serve the following purposes: (i) helping patent examines determine whether 
the claimed invention constitutes an invention that is excluded from patentability under Articles 27(2) 
and (3) of the Trade Relate Aspects of Intellectual property Agreement, (ii) enhancing the ability of 
countries to track bad patents and in the instances where they are granted and challenge the same, (iii) 
reducing  instances  of  bad  patents  and  (iv)  improving  compliance  with  their  national  laws  on  Prior 
Informed  Consent  and  fair  and  equitable  benefit  sharing  prior  to  accessing  a  biological 
resource/associated  traditional  knowledge.  Article  29  already  obliges  members  to  require  that  patent 
applicants disclose the invention in a manner sufficiently clear and complete for the invention to be 
carried out by a person skilled in the art and may require the applicant to indicate the best mode to carry 
out  the  invention  known  to  the  inventor.  An  obligation  to  disclose  source  and  country  of  origin  of 
biological  resources  and/or  traditional  knowledge  used  in  an  invention  would  play  a  crucial  role  in 
ensuring patent quality.   10 
over their biological resources with the main objective of the conservation of biological 
diversity, sustainable use of its components and fair and equitable sharing of benefits 
arising out of utilization of genetic resources.
36  
 
A  few  WTO  members  maintain  that  by  incorporating  the  patenting  of  micro-
organisms
37 and micro-biological processes, the TRIPS Agreement, has violated the basic 
tenet of patent law, that while discoveries are not patentable, inventions are.
38 Literally 
translated, discovery is new insight into a product or process that already exists in nature 
while  an  invention  involves  the  production  a  new  product/process  hitherto  unknown. 
There is immediate need for a clearer understanding of which stages of research into 
genetic  resources,  including  genetic  parts  and  components,  constitute  ‘discovery’  and 
which fulfill the requirement of an invention.
39 It is questionable whether the mere act of 
‘isolation’  of  genetic  material  from  its  natural  source,  as  legally  established  in  many 
developed countries, would satisfy the test of non-obviousness or inventive step.
40 In this 
background,  developing  countries,  including  India,  face  a  dilemma  with  defining  the 
contours  of  biotechnological  inventions,  the  patenting  of  micro-organisms  and  non-
                                                 
36 See, Article 1, 3, 15, 16(5) and 8(j) of the Convention on Biological Diversity 
37 With regard to what action should be taken in the World Trade organization on the treatment of micro-
organisms,  the  following  view  has  been  expressed:  (i)  There  is  no  scientific  or  other  rationale  for 
distinguishing between plants and animals on the one hand and micro-organisms on the other (Kenya on 
behalf  of  the  African  Group,  IP/C/W/163)  and  micro-organisms,  like  other  biological  and  living 
organisms, should be excluded from patentability, Kenya, IP/C/M/28, para. 152), (ii) the coverage of the 
term ‘micro-organism’ should be clarified, in particular so as to exclude cell lines, enzymes, plasmids, 
cosmids and genes (Kenya, IP/C/M/28, para. 152), (iii) individual members should determine and apply 
the term in their national jurisdiction in accordance with Article 1.1 of the Budapest Treaty and not seek 
to define the term. Patent experts have a fairly clear idea of the term but the issue is complex and 
therefore it is better left to each members patent offices and experts to determine (Korea, IP/C/M/35, 
para. 225), (iv) it should be left to national policy to decide what are patentable micro-organisms (India, 
IP/C/W/161),  given  that  micro-organisms  could  be  excluded  from  patentability  under  Article  27(2) 
(IP/C/W/161) 
38 Kenya on behalf of the African Group, IP/C/W/163 
39 Malaysia, IP/C/M/32, para. 143 
40 India, IP/C/M/29, para. 161. Mere discoveries, not involving human intervention, are not considered 
patentable subject-matter (Japan, IP/C/M/29 para. 151, Switzerland, IP/C/M/30, para. 164). It has been 
elaborated that if, however, naturally occurring things, such as chemical substances or micro-organisms, 
have been first isolated artificially from their surroundings in nature they are capable of constituting an 
invention. It has also been said that if the subject-matter of a patent  has  involved  sufficient human 
intervention, such as isolation or purification, and if the isolated or purified subject-matter is not of a 
previously recognized existence, then it is considered an invention (EC, IP/C/W/254, Japan, IP/C/M/29 
para. 151, United States, IP/C/M/29 para. 186)   11 
biological  processes  in  their  national  legislation.
41  At  the  outset,  India  excludes  the 
discovery of any living or non living thing or non living substance occurring in nature,
42 
plants  and  animals  in  whole  or  any  part  including  seeds,  varieties  and  species  and 
essentially biological processes for production or propagation of plants and animals other 
than micro-organisms from the ambit of patentability.
43  
 
The  most  important  criteria  for  judging  patent  eligibility  is  that  of  ‘non-
obviousness’ or ‘inventive step,’ this involves a question of fact and degree and is to be 
answered  in  accordance  with  the  general  policy  of  the  Patents  Act  to  reward  and 
encourage invention without inhibiting improvements of existing technology by others.
44 
The question to be asked is: “Was it for practical purposes obvious to the skilled worker, 
in the field [of technology] concerned, in the state of knowledge existing at the date of 
the  patent  to  be  found  []  then  available  to  him,  that  he  would  or  should  make  the 
                                                 
41 In Diamond v. Chakrabarty, the Supreme Court in the United States held that a live, human made micro-
organism was patentable under 35 USC Article 101 (“whoever invents or discovers any new and useful 
process, machine, manufacture or composition of matter, or any new and useful improvement thereof, 
may obtain a patent therefore, subject to the conditions and requirements or this title”). The test set down 
by the court of patentable subject matter in this area is whether the living matter is the result of human 
intervention,  “his  claim  is  not  to  a  hitherto  unknown  natural  phenomenon,  but  to  a  non-naturally 
occurring manufacture or composition of matter-a product of human ingenuity having a distinctive name, 
manufacture or use”. The Supreme Court chose an expansive definition of the term ‘manufacture’
41 the 
court further held that the congress intended statutory subject matter to ‘include anything under the sun 
that is made by man, 447 US at 309, citing S.Rep.No.82-1979, at 5 (1952); H.R.rep.No. 82-1923, at 
6(1952). Non-obviousness under 35 USC 103 requires an invention to be beyond the ordinary abilities of 
a skilled artisan knowledgeable in the appropriate field. In Graham v John Deere Co, 383 US 1, 11 
(1966) the Supreme Court held that non-obviousness requires a three part inquiry: (i) the scope and 
content of the prior art are to be determined, (ii) differences between the prior art and the claims at issue 
are to be ascertained, and (iii) the level of ordinary skill in the pertinent art resolved. The federal court 
has filled the gap in part through its “suggestions test”, which focuses on the extent to which “the prior 
art would have suggested to one of ordinary skill in the art that this process should be carried out and 
would have a reasonable likelihood of success (brown and Williamson Tobacco Corp v Philip Morris, 
Inc., 229 F. 3d 1120, 1124 (Fed. Cir 2000). The Supreme Court also identified a number of “secondary 
considerations,” including ‘commercial success, long felt but unsolved needs, and failure of others,” that 
“may have relevancy” as “indica of obviousness (Graham, 383 US at 17-18). The Federal Circuit has 
required considerations of any evidence of these secondary characteristics and, at times, has given them 
considerable weight as means for overcoming that might otherwise be prima facie  case of obviousness 
under the primary Graham test. 
42 Section 3©, Patents [Amendment] Act, 2002. 
43 Section 3(j), Patents [Amendment] Act, 2002 
44 See, Societe Technique De Pulverisation Step v. Emson Europe (1993) RPC 513 (CA)   12 
invention the subject of the claim concerned?”
45 The requirement that an invention be 
non-obvious  preserves  the  public  domain  by  creating  a  patent  free  zone  around  the 
existing  state  of  art.  Usefulness
46  was  recognized  as  one  of  three  pre-requisites  in 
establishing patentability, even in Biswanath Prasad Radhey Shyam v. Hindustan Metal 
Industries
47 it was held that “[] that Section 26(1)(f) of the 1911 Act recognized the lack 
of utility as one of the grounds on which a patent could be revoked.” Thus, there must be 
an invention applied to produce a practical result
48 that is, it must be capable of industrial 
applicability;  an  invention  must  be  a  ‘new  and  useful’  ‘method  or  manner’  of 
manufacture.  
 
The  definition  of  ‘invention’  was  amended  in  2002
49  in  accordance  with  the 
TRIPS  Agreement  to  mean  a  new  product  or  process  involving  an  inventive  step  (a 
feature that makes the invention not obvious to a person skilled in the art)
50 and capable 
of industrial application
51 (capable of being made or used in an industry).
52 The combined 
effect of these definitions was to provide a progressive meaning to the term invention, 
one  which  would  encompass  just  about  every  new  creation  in  any  field  of  scientific 
endeavor, provided it was not prohibited under Section 3 of the Act.
53 Under the 2004 
Ordinance, the scope of patentable inventions has been expanded, beyond the purview of 
process, to mean a patent for ‘any invention,’
54 that is either product or process. The 
                                                 
45 See, Halsbury 3
rd Edition, Vol. 29, p. 42 referred to by Vimadalal, J at the Bombay High Court in 
Earbwerke Hoechst and B Coproration v. Unichem Laboratories AIR 1969 Bom. 225.  
46 Under 35 USC 101, it means that the invention must be minimally operable towards some practical 
purpose. “The claimed invention as a whole must accomplish a practical application. That is, it must 
produce ‘a useful, concrete and tangible result’.” State Street 149 F. 3d at 1373, 47 USPQ2d at 1601-2 
47 AIR 1982 SC 144 
48 Harwood v. Great Northern Railway Company, (1864-65) 11 HLC 654 
49 Section 2(1)(j) of the Patents Act, 1970 defined an invention as follows: “Invention means any new and 
useful-(i) art, process, method or manner of manufacture, (ii) machine, apparatus or other article, (iii) 
substance produced by manufacture, and includes any new and useful improvement of any of them, and 
an alleged invention.”  
50 Section 2(1)(ja) 
51 Section 2(1)(j) 
52 Section 2(1)(j) 
53 Asian Patent Attorneys Association Newsletter, June 2003, p. 169 
54 Section 2(1)(m)    13 
definition  of  an  inventive  step  has  been  qualified  to  “a  feature  of  an  invention  that 
involves technical advance as compared to the existing knowledge or having economic 
significance or both [emphasis added] and that makes the invention not obvious to a 
person skilled in the art.” ‘Technical advance as compared to the existing knowledge’ and 
‘economic significance’ are terms of art subject to judicial interpretation. 
 
With  the  introduction  of  product  patents  the  regime  for  Exclusive  Marketing 
Rights has been revoked. Section 5 as amended in 1999 provided patents for methods or 
processes of manufacture. It provided that inventions, (a) claiming substances intended 
for use, or capable of being used, as food
55 or as medicine or drug
56, or (b) relating to 
substances prepared or  produced by  chemical processes which includes ‘biochemical, 
biotechnological and microbiological processes’
57 (including alloys, optical glass, semi-
conductors, inter-metallic compounds), were to be denied a patent in respect of the claims 
for the substances themselves.
58 The claim for patenting a substance itself intended for 
use, or capable of being used, as medicine or drug (except all chemical substances that 
are  ordinarily  used  as  intermediaries  in  the  preparation  and  manufacture  of  any  of 
medicines or substances, Section 2(l)(v)), could be made under Chapter IV of the Act 
dealing  with  Exclusive  Marketing  Rights.
59  Exclusive  Marketing  Rights  provided  a 
means  for  accepting  patent  applications  for  pharmaceutical  and  agricultural-chemical 
products, which were not to be referred to the examiner for making a report until 31
st 
                                                 
55 Omitted under 2004 Ordinance, “Food means any article of nourishment for human consumption and 
also includes any substance intended for the use of infants, invalids or convalescents as an article of food 
o drink (Section 2(g))” 
56 Omitted under the 2004 Ordinance, Section 2(l): “Medicines and drugs, include, (i) all medicines for 
external and internal use of human beings or animals, (ii) all substances intended to be used for or in the 
diagnosis, treatment, mitigation or prevention of diseases in human beings or animals, (iii) all substances 
intended to be used for or in the  maintenance of public health, or the prevention or control of any 
epidemic disease among human beings or animals, (iv) insecticides, germicides, fungicides, weedicides 
and all other substances intended to be used for the protection or preservation of plants, (v) all chemicals 
substances which are ordinarily used as intermediates in the preparation or manufacture of the medicines 
or substances above referred to.” 
57 2002 Amendment 
58 Section 5(1), Patents Act 1970, subject to the 1999 Amendment 
59 Section 5(2) Patents Act 1970, subject to the 1999 Amendment   14 
December, 2004.
60 Only the application for grant of exclusive rights to sell or distribute 
the article or the substance could be referred for an examiner’s report. An Exclusive 
Marketing Right would grant the patent owner the exclusive right by himself, his agents 
or licensees to sell or distribute in India the article or the substance on or from the date of 
approval granted by the Controller until a period of five years or until the date of grant of 
patent or the date of rejection of application for the grant of patent, whichever is earlier.  
 
Under the 2004 Ordinance every application for the grant of Exclusive Marketing 
Right’s filed before January 1
st 2005, in respect of a claim for a patent covered under S. 
5(2) shall be deemed to be treated as a request for examination for grant of patent under 
11B(3).
61 The application in respect of which exclusive rights have been granted before 
the 1
st of January 2005 shall be examined for the grant of patents immediately on the 
commencement of the Ordinance.
62 Every exclusive right to sell or distribute an article or 
substance in India granted before 1
st January 2005 will continue to be effective with the 
same terms and conditions of the grant.
63 Although the 20-year term will be counted from 
the date of the patent application, the protection will be effective from the date of grant of 
patent, that is, the protection based on patents granted to mailbox applications will be 
effective only prospectively from the date of grant of the patent and not retrospectively 
from  the  date  of  application.  Infringement  proceedings  will  not  be  allowed 
retrospectively and patent owners (for patent rights granted under Section 5(2)) shall be 
entitled to receive only a reasonable royalty from enterprises which were producing and 
marketing the patent product prior to the 1
st of January 2005 and which continue to so 
do.
64 
                                                 
60 Section 5(2) 
61 Section 77(1) 
62 Section 77(3), See “All suits relating to infringement of the exclusive right granted before the 1
st of 
January 2005 shall be dealt with in the same manner as if they were suits concerning infringement of 
patents”,  Section  77(4).  “The  examination  and  investigation  required  as  carried  out  for  the  grant  of 
exclusive right shall not be deemed in any way to warrant the validity of any grant of exclusive right to 
sell or distribute, and no liability shall be incurred by the central government or any officer for the same”, 
Section 77(5). 
63 Section 77(2) 
64 Section 11A(7), Patents [Amendment] Act 2005   15 
 
The Act enumerated what are ‘not’ inventions and those inventions that are not 
patentable.
65 Inventions, the primary or intended use or commercial exploitation of which 
could be contrary to ‘public order
66 or morality’ or which cause serious prejudice to 
human, animal or plant life or health or to the environment are not patentable.
67 India has 
incorporated the qualifier of ‘serious prejudice’ to human, animal and plant life or health 
and has not adopted the standard of ‘necessity’ to protect ‘ordre public or morality’ in 
comparison with Article 27.2.
68 While the TRIPS agreement is silent on the issue of the 
patentability  of  ‘new  uses’  of  known  substances,  including  second  or  subsequent 
therapeutic  uses  for  known  pharmaceutical  products,
69  the  2004  Patents  Ordinance 
qualified ‘new use of a known substance’ with the threshold requirement of ‘mere.’
70 
This  widened  the  scope  of  patentability  by  narrowing  the  exception  to  it.  It  allowed 
patents to be  granted for second use or new formulations of existing  molecules.
71  In 
response  to  this  concern  the  Patents  [Amendment]  Act  (2005)  has  re-formulated  the 
exception,  to  the  stricter  standard  of  a  “mere  discovery  of  a  new  form  of  a  known 
substance  which  does  not  result  in  the  enhancement  of  the  known  efficacy  of  that 
substance [emphasis added] or the mere discovery of any new property or new use for a 
known substance or of the mere use of a known process, machine or apparatus is also 
excluded  from  patentability  unless  such  known  processes  result  in  a  new  product  or 
employ at least one new reactant.” “Salts, esters, ethers, polymorphs, metabolites, pure 
form, particle size, isomers, mixtures of isomers, complexes, combinations, and other 
                                                 
65 WTO-TRIPS Obligations and Patents Amendment in India, K.D. Raju, Page, 228 
66 “[Ordre Public] may be interpreted as being narrower than ‘public order’ or ‘public interest,’” Patents 
Rights, ‘Intellectual Property and International Trade,’ page 192 
67 Section 3(b), 2002 Amendment 
68 Prior to its substitution, clause (b) read as under: (b) an invention the primary or intended use of which 
would be contrary to law or morality or injurious to public health 
69 A potential weapon in lengthening patent protection past the 20 year minimum 
70 The mere discovery of any new property or ‘mere’ new use for a known substance or of the mere use of a 
known process, machine or apparatus is also excluded from patentability unless such known processes 
result in a new product or employ at least one new reactant (Section 3(d)) 
71  http://www.ip-watch.org/weblog/index.php?p=33&res=800_ff&print=0:  “Companies  invest  heavily  in 
‘evergreening,’  that  is,  making  some  small  change  to  a  medicine  and  seeking  a  new  patent.”  Tight 
definition of patentability allows affordable generic versions of drugs to be produced on the expiry of the 
20 year term   16 
derivatives of known substances shall be considered to be the same substance, unless they 
differ significantly in properties with regard to efficacy.”
72 The term ‘efficacy’ or the 
variables to interpret or evaluate it remain un-defined. The Act excludes any process for 
the  medicinal,  surgical,  curative,  prophylactic,  diagnostic
73,  therapeutic
74  or  other 
treatment of human beings or any process for the similar treatment of animals excluding 
plants
75 to render them free of disease or to increase their economic value or that of their 
products
76  from  the  realm  of  patentability,  in  consonance  with  Article  27(3)(a).  The 
forms  of  treatment  are  exponentially  defined.  Under  the  2004  Ordinance  a  computer 
programme per se (excluding its technical application to industry or a combination with 
hardware)  along  with  mathematical  method  or  business  method  or  algorithm  were 
excluded  from  patentability.
77  An  argument  against  the  provisions  of  Section  3(k) 
stipulated that since commercial software has ‘some’ industrial application and that all 
such  applications  can  be  construed  as  technical  applications  it  opens  up  software,  in 
general, to patenting.
78 It posed to give rise to multinational monopoly by protecting the 
‘idea’  on  which  the  software  is  developed,  further  (cost  of  developing  software 
multiplies,  patent  thickets  form,  practice  of  defensive  patenting  commences,  royalty 
stack-up’s occur).
79 This is distinct from copyright protection (Section 14 (b), Copyright 
Act, 1957), which apart from being automatically guaranteed, protects the expression of a 
‘function or an idea in the computer code’.
80 It is emphasized that the Indian software 
industry would be much better served by taking the Free or Open Source route.
81 As per 
                                                 
72 Patents Amendment Act (2005), Explanation to Section 3(d) 
73 Inserted, 2002 Amendment 
74 id 
75 Omitted, 2002 Amendment 
76 Section 3(i) 
77 Sections 3(k) and (ka) respectively 
78http://www.smh.com.au/news/Soapbox/Software-patents-a-blow-to 
India/2005/02/17/1108609336187.html?oneclick=true  
79 a dense web of overlapping patents intellectual property rights  
80 http://www.linux-india.org/index.pl?id=3651&isa=Newsitem&op=show 
81http://www.smh.com.au/news/Soapbox/Software-patents-a-blow-to 
India/2005/02/17/1108609336187.html?oneclick=true   17 
the new Act, the clarification relating to the patenting of software related inventions has 
been deleted.  
 
In keeping with the issue of ‘biopiracy’ the Indian Government under the 2002 
Amendment  also  excluded  an  invention  which,  in  effect,  is  traditional  knowledge  or 
which  is  an  aggregation  of  duplication  of  known  properties  of  traditionally  known 
component(s),  Section  3  (p).
82  India’s  initiative  in  fighting  ‘bio-piracy’  was  further 
fortified  under  the  2004  Ordinance  with  the  inclusion  of  two  new  provisions  for 
opposition at the pre and post grant levels. These are, failure to disclose or the incorrect 
mention of the source of geographical origin of biological material used for the invention 
in question and the invention claimed is anticipated by knowledge, oral or otherwise, 
available within any local or indigenous community in India or elsewhere in the world.  
 
2.3.3.  Rights conferred and exceptions to rights conferred: 
Article  28  guarantees  exclusive  rights  to  patent  owners,  defined  in  a  negative 
manner as the faculty to prevent certain acts relating to the invention. Exceptions counter-
balance  the  monopoly  rights  grated  by  the  patent.  The  preamble,  principles  and 
objectives  of  the  Agreement  may  be  drawn  on  to  carve  out  exceptions  and  grant 
compulsory  licenses.  Article  30
83  enunciates  limited  exceptions,
84  given  that  such 
                                                 
82 Also excluded under Section 3 are: an invention which is frivolous or which claims anything obvious 
contrary to well established natural laws (3(a)), a substance obtained by a mere admixture resulting only 
in the aggregation of the properties of the components thereof or a process for producing such substance 
(3(e)),  the  mere  arrangement  or  re-arrangement  or  duplication  of  known  devices  each  functioning 
independently of one another in a known  way (3(f)), a method of agriculture or horticulture (3(h)), 
literary,  dramatic,  musical  or  artistic  work  or  any  other  aesthetic  creation  whatsoever  including 
cinematographic works and television productions (3(l)) [2002 Amendment], a mere scheme or rule or 
method of performing mental act or method of playing game (3(m)) [2002 Amendment], a presentation 
of information (3(n)) [2002 Amendment], topography of integrated circuits (3(o)) [2002 Amendment] 
83 In Canada – Patent Protection of Pharmaceutical Patents (WT/DS114/R: 17 March 2000-Panel Report), 
the panel found that the conditions for the application of Article 30 apply cumulatively (emphasis added), 
each  being  a  separate  and  independent  requirement  that  must  be  satisfied.  Both  the  goals  and  the 
limitations stated in articles 7 and 8.1 must obviously be borne in mind when interpreting the limiting 
provisions of the Trade Related Aspects of Intellectual Property Rights Agreement.  
84 In Canada – Patent Protection of Pharmaceutical Patents (WT/DS114/R: 17 March 2000-Panel Report), 
‘limited’ is to be measured by the extent to which the exclusive rights of the patent owner have been 
curtailed, focusing on the extent to which legal rights have been curtailed, rather than the size or extent of 
the economic impact   18 
exceptions (i) do not unreasonably conflict with a normal exploitation of the patent
85 and 
(ii) do not unreasonable prejudice the legitimate interests of the patent owner taking into 
account the legitimate interests
86 of the third parties. Article 31 enumerates refusal to 
deal, emergency and extreme urgency, anti-competitive practices, non-commercial use 
and dependent patents’ as possible grounds for the concession of patents rights without 
the authorization of a patent holder for “other use” barring the exceptions provided for 
under Article 30. It provides a detailed set of conditions
87 to be met for the grant of a 
compulsory license. These exceptions once interpreted together, ‘may even expand’
88 the 
                                                 
85 In Canada – Patent Protection of Pharmaceutical Patents (WT/DS114/R: 17 March 2000-Panel Report), 
the normal practice of exploitation by patent owners, as with owners of any other intellectual property 
right, is to exclude all forms of competition that could detract significantly from the economic returns 
anticipated from a patent’s grant of market exclusivity 
86 In Canada – Patent Protection of Pharmaceutical Patents (WT/DS114/R: 17 March 2000-Panel Report), 
‘legitimate interests’ in this context, must be defined in the way that it is often used in legal discourse - as 
a  normative  claim  calling  for  protection  of  interests  that  are  ‘justifiable’  in  the  sense  that  they  are 
supported by relevant public policies or other social norms. 
87  The  requirement  of  a  proposed  user  to  made  efforts  within  a  reasonable  period  of  time  to  obtain 
authorization from the right holder on reasonable commercial terms and conditions for a licenses may be 
waived by a member country in the event of a national emergency, circumstances of extreme urgency or 
in the case of public non-commercial use (Article 31(b)), the scope and duration of such use shall be 
limited  to  the  purpose  for  which  it  was  authorized  (Article  31(c)),  such  use  shall  be  non-exclusive 
(Article 31(d)), such use shall be non-assignable, except with that part of the enterprise or goodwill 
which enjoys such use (Article 31(e)), such use shall be authorized predominantly for the supply of the 
domestic market of the member authorizing such use (Article 31(f)), subject to the adequate protection of 
the legitimate interests of the person so authorized, such use will be terminated if circumstances which 
led to it cease to exist and are unlikely to reoccur (Article 31(g)), the right holder shall be paid adequate 
remuneration  in  the  circumstances  of  each  case,  taking  into  account  the  economic  value  of  the 
authorization and under Article 31(k) the need to correct anti-competitive practices may be taken into 
account in determining the amount of remuneration (Article 31(h)) and members are not obliged to apply 
Articles 31(b) and (f) where such use is permitted to remedy a practice determined after judicial or 
administrative process to be anti-competitive (Article 31(k)) 
88 Intellectual  Property  Rights  and  International  Trade-the  TRIPS  Agreement,  ‘Universal  minimum 
standards of intellectual property protection under the TRIPS component of the WTO Agreement’ Carlos 
Correa and A.Yusuf, Page 34   19 
pre-existing grounds for limiting a patentee’s exclusive right under Article 5A (2-4)
89 of 
the Paris Convention. 
 
The general purpose for granting a Compulsory License, in India, is to ensure that 
a patented invention is worked on a commercial scale without undue delay to the fullest 
extent that is reasonably practicable, while not unfairly prejudicing the interest of the 
person (for the time being) working or developing a patent.
90 Compulsory licenses also 
act as an essential tool for governments in facilitating their public health policies. Under 
Section 83(d) India recognizes that patents should not impede the protection of public 
health and nutrition and should act as an instrument to promote public interest, especially, 
in sectors of vital importance for socio-economic and technological development. India 
also recognizes that patents are granted to make the benefit of the patented invention 
available at reasonably affordable prices to the public, Section 83(g) reiterated in Section 
90(1)(iii).  
 
The Ministerial Declaration on ‘The TRIPS Agreement and Public Health’ (14
th 
of November, 2001) acknowledged the gravity of the health problems afflicting many 
developing  and  least  developed  countries,  especially  those  resulting  from  HIV/AIDS, 
tuberculosis,  malaria  and  other  epidemics.
91  Many  developing  countries  and  least 
developed countries cannot manufacture either active ingredients or formulations, due to 
the lack of technology, equipment, human resources or for want of economic viability of 
domestic production. Paragraph 6 of the Declaration recognized that WTO members with 
insufficient or no manufacturing capacity could face difficulties in making effective use 
                                                 
89 Article 5A(3)- Prohibits forfeiture on grounds of abuse without first trying the remedy of compulsory 
licensing,  even  specifying  that  members  have  to  allow  for  two  years  from  the  grant  of  the  first 
compulsory license before proceedings for forfeiture can be instituted. Article 5A(4)- Requires another 
time restriction namely, no compulsory license, on grounds of failure to work or insufficient working can 
effectively be applied for prior to three years from the grant of the patent or four years from the date of 
filing of the patent application, whichever is longer. The time restriction applies only to the particular 
case of the application for compulsory licenses on grounds of non-working or insufficient working. An 
application for compulsory licenses on such grounds is to be refused if the patentee justifies his inaction 
by legitimate reasons. Such a compulsory license is to be non-exclusive and non-transferable except in 
the case of the business entity itself. 
90 Section 89 
91 Paragraph 1   20 
of  compulsory  licenses  under  Article  31(f)  of  the  TRIPS  Agreement,  given  that 
compulsory licensing “shall be authorized predominantly for the supply of the domestic 
market.” The Article forbids producer countries from exporting a ‘predominant’ amount 
or more of their generic pharmaceutical products to importing countries. Under paragraph 
6 the Declaration instructed the TRIPS Council to find an ‘expeditious’ solution to this 
problem. The Decision adopted by the General Council on the 30
th of August 2003, chose 
the mechanism of an ‘interim waiver’
92 of Article 31(h) and Article 31(f) to “an extent 
necessary for the purposes of the production of pharmaceutical product and its concurrent 
export  to  an  eligible  importing  country.”
93  Article  31(b)  requiring  the  grant  of  a 
compulsory license to follow an “authorization” from the patent owner on “reasonable 
commercial  terms”  within  a  “reasonable  period  of  time”  (except  in  the  event  of  a 
‘national emergency, extreme urgency or public non-commercial use’
94 or to remedy an 
anti-competitive practice under Article 31(k)) and Article 31 (h) requiring the payment of 
compensation taking into account the economic value of the authorization, have not been 
waived.
95 Where Article 31(b) cannot be waived the “reasonable period of time” must be 
reduced to expedite the access to pharmaceutical products.
96 The 2005 Act, provides a 
period  of  not  exceeding  6  months.
97  The  waiver  of  Article  31(h)  needs  to  be 
implemented, domestically, to prevent a claim for compensation in accord with national 
law.  Where  a  compulsory  license  is  granted  in  the  exporting  country,  the  Decision 
warrants  that  ‘adequate  remuneration’  taking  into  account  the  economic  value  of  the 
authorization under Article 31(h), may be paid in that member taking into account the 
                                                 
92 Temporarily  suspends  Treaty  Obligations  under  the  Trade  Related  Aspects  of  intellectual  Property 
Rights, (Article 57 of the Vienna Conventions on the law of treaties) 
93 Paragraph 2 
94 Declaration (5C), “Each member has the right to determine what constitutes a national emergency or 
other circumstances of extreme urgency, it being understood that public health crises, including those 
relating to HIV/AIDS, tuberculosis, malaria and other epidemics, can represent a national emergency or 
other circumstances of extreme urgency.”  
95 “The right holder shall be paid adequate remuneration in the circumstances of each case, taking into 
account the economic value of the authorization.” Further, under Article 31(k) anti-competitive practices 
may be taken into account in determining the remuneration 
96 Also provided for in the Preamble to the Decision, “Where eligible importing members seek to obtain 
supplies under the system set out in this decision, the importance of a rapid response to those needs…” 
97 Explanation to Section 84(6)(iv)   21 
economic value to the importing country of the use authorized in the exporting country 
(paragraph 3).   
  
Section 92A(1) of the Ordinance provided that compulsory licenses should be 
available for manufacture and export of patented pharmaceutical products to any country 
having insufficient or no manufacturing capacity in the pharmaceutical sector “provided 
[the]compulsory license has been granted in such country”. The Decision provides two 
alternative ways to establish ‘insufficient or no manufacturing’ capacity (not applicable 
to  Least  Developed  Countries),  that  is  (a)  the member  has  established  that  it  has  no 
manufacturing  capacity  in  the  pharmaceutical  sector  or  (b)  the  member  has  some 
pharmaceutical  manufacturing  capacity,  has  examined  its  capacity  and  found  that, 
excluding  any  capacity  owned  or  controlled  by  the  patent  owner,  it  is  currently 
insufficient for the purposes of meeting its needs. What manufacturing capacity means in 
either of the options is open to interpretation. It does not include the requirement that an 
importing country must face a genuine public health problem or that the country lack the 
resources to purchase needed medicines from the manufacturer.  
 
The latter half of the Section, it appeared, called for an examination by the Indian 
authorities of whether an importing country had complied with the TRIPS obligation. It 
was widely argued that it was not for the exporting country to lay down conditions as to 
how the importing country should comply with the TRIPS provisions. The Ordinance did 
not  establish  a  system  which  “as  a  matter  of  ‘right”
98  could  provide  the  Indian 
pharmaceutical manufacturer with a compulsory license for manufacture and export. So 
hence, an amendment to the Ordinance has been introduced by the Patents [Amendment] 
Act 2005 Act. Now, compulsory licenses are available for the manufacture and export of 
patented pharmaceutical products to any country having ‘insufficient or no manufacturing 
capacity’ in the pharmaceutical sector for the concerned product to address public health 
problems, provided that compulsory licenses have been granted by the importing country 
“or such country has by notification or otherwise allowed importation of the patented 
pharmaceutical product from India.”  
                                                 
98 id   22 
 
In general, the TRIPS Agreement should be interpreted and implemented in a 
manner supportive of the WTO member’s rights to protect public health, and in particular 
to promote access to medicines for all.
99 Each provision of the Agreement should be read 
in light of the objectives and principles set forth in Article 7 and 8. Such an interpretation 
finds support in the Vienna Convention on the Law on Treaties which establishes that “a 
treaty shall be interpreted in good faith in accordance with the ordinary meaning to be 




2.4.  Conclusion: Important changes proposed in the Patents [Amendment]Act, 2005 
India has amended its Patents legislation successively to bring it in accord with 
the  TRIPS  Agreement,  the  latest  of  the  three  amendments  being  the  Patents 
[Amendment] Act (2005). The final deadline of the 1
st of January 2005 imposed under 
the TRIPS Agreement has been met with the introduction of a product patents regime. 
While the new Act has been hailed as a step towards facilitating greater ‘innovation’ it 
has also been criticized as culminating the supply of cheap medicines to the poor.  
 
The 2005 Act has sought to amend the 2004 Ordinance (26
th December, 2004). 
Sections 3(k) and 92(1)(A) of the Ordinance pertaining to software patenting and the 
requirement of ‘authorization’ respectively, which purported to impose a ‘TRIPS plus’ 
requirement  have  been  omitted.  The  Act  has  restricted  the  scope  of  patentability  by 
modifying  the  definition  of  ‘inventive  step,’  it  has  attempted  to  curb  “evergreening” 
patents.  Through  the  Act,  the  government  has  attempted  to  preserve  a  larger  public 
domain or ‘patent free zone’ around the existing state of art from that provided for under 
the Ordinance. Parallel imports, to facilitate access to cheaper drugs have been provided 
for  bereft  of  the  earlier  required  “duly  authorized  by  the  patentee”  under  Section 
107A(b).  Procedural  changes  have  been  incorporated  with  a  period  of  6  months 
                                                 
99 Declaration on the TRIPS Agreement and Public Health, Paragraph 4 
100 Article 31   23 
quantifying  ‘reasonable  period’  in  relation  to  compulsory  licenses  under.  Reasonable 
royalty has been recognized at 5% for the production of ‘on patent’ generic drug. A right 
to representation has been provided for at the pre grant opposition level and the grounds 
to invoke pre-grant opposition have been expanded. 
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2.5.  Procedure 
2.5.1.  Compulsory  Licenses 
GROUNDS FOR GRANT OF A PATENT: After expiration of 
3 years from the date of sealing of a patent, any person 
interested may apply to the controller for the grant of CL, on 
any  of  the  following  grounds:  (i)  that  the  reasonable 
requirements  of  the  public  with  respect  to  the  patented 
invention  have  not  been  satisfied,  or  (ii)  that  the  patented 
invention  is  not  available  to  the  public  at  a  reasonably 
affordable  price,  or  (iii)  “that  the  patented  invention  is  not 
worked in the territory of India” [2002 Amendment], S. 84(1). 
APPLICANT: any person, notwithstanding that he is already a 
licensee, S. 84(2). 
CONSIDERING  THE  APPLICATION:  the  controller  shall 
take into account, the nature of the invention, the time which 
has elapsed since the sealing of  the patent and the  measures 
already taken by the patentee or any licensee to make the full 
use of the invention, the ability of the applicant to work the 
invention to the public advantage, the capacity of the applicant 
to  undertake  the  risk  in  providing  capital  and  working  the 
invention  if  the  application  were  granted,  “whether  the 
applicant  has  made  efforts  to  obtain  a  license  on  reasonable 
terms and conditions and such efforts have been unsuccessful in 
a  reasonable  period  as  the  Controller  deems  fit”,  shall  not  
ordinarily exceed 6 months [2002 Amendment], determined by 
controller (except, the last requirement shall not apply in cases 
of a national emergency, circumstances of extreme urgency, or 
in case of public non-commercial use or on establishment of a 
ground  of  anti-competitive  practices  adopted  by  the  patentee 
prior to the application), S. 84(6). The controller, if satisfied, 











If, upon consideration of the evidence, 
the Controller is satisfied that a prima 
facie case has not been made out for 
the making of an order under Sections 
84  he  shall  notify  the  applicant 
accordingly,  and  unless  the  applicant 
requests  to  be  heard  in  the  matter, 
within 1 month from the date of such 
notification, the Controller shall refuse 
the application [Rule 97(1)]. (2) If the 
applicant requests for a hearing within 
1  month,  the  Controller  shall,  after 
giving the applicant an opportunity of 
being  heard,  determine  whether  the 
application may be proceeded with or 
whether  it  shall  be  refused  [Rule 
97(2)]. 
 
Where, (a) by reason of the refusal of the 
patentee to grant a license on reasonable 
terms (i) an existing trade or industry or 
the development of and establishment of 
any  trade  or  industry  in  India  is 
prejudiced  [];  (ii)  the  demand  for  the 
patented article has not been met to an 
adequate  extent  or  on  reasonable  terms 
(‘From manufacture in India’, 1970 Act, 
Omitted under the 2002 Amendment); 
(iii) a market for export of the patented 
article manufactured in India is not being 
supplied  or  developed;  (iv)  the 
establishment  or  development  of 
commercial  activity  in  India  is 
prejudiced; (b) if by reason of conditions 
imposed  upon  the  grant  of  licenses,  or 
upon  the  purchase,  hire  or  use  of  the 
patented article/process, the manufacture, 
use or sale of materials not protected by 
the  patent,  or  the  establishment  or 
development of any trade or industry in 
India  is prejudiced;  (c)  “if  the patentee 
imposes  a  condition  upon  the  grant  of 
licenses  under  the  patent  to  provide 
exclusive  grant  back,  prevention  to 
challenges  to  the  validity  of  patent  or 
coercive  package  licensing  “[2002 
Amendment]; (d) (‘If the demand for the 
patented article in India if being met to a 
substantial  extent  by  importation  from 
abroad  by,’  1970  Act,  Omitted  under 
the  2002  Amendment)  if  the  patented 
invention  is  not  worked  in  India  on  a 
commercial scale to an adequate extent 
or  the  fullest  extent  that  is  reasonably 
practicable;  (e)  “if  the  working  of  the 
patented  invention  in  the  territory  of 
India  on  a  commercial  scale  is  being 
prevented or hindered by the importation 
from abroad of the patented article by the 
patentee  or  person claiming under him, 
persons directly or indirectly purchasing 
from him, or other persons against whom 
the patentee is not taking or has not taken 
proceedings  for  infringement”  [2002 
Amendment], S. 84(7) 
Where the controller is satisfied that the time which 
has elapsed since the sealing of the patent has for any 
reason been insufficient to enable the invention to be 
worked on a commercial scale to an adequate extent 
or  to  enable  the  invention  to  be  so  worked  to  the 
fullest extent that is reasonably practicable, he may, 
adjourn the further hearing of the applicant for such 
period not exceeding 12 months as appears to him to 
be  sufficient  for  the  invention  to  be  so  worked, 
subject to proviso,  S. 86(1) 
If the controller is satisfied that a prima facie case has 
been made out under Section 84 the controller shall 
direct the applicant to serve copies of the application 
to the patentee and any other person interested in the 
patent  and  shall  publish  the  application  in  the 
official journal [2004 Ordinance], S. 87(1). A notice 
of opposition shall be sent to the Controller within 2 
months  from  the  date  of  the  publication  [2004 
Ordinance]  of  the  application  [Rule  98(1)].  The 
notice  of  opposition  shall  include  the  terms  and 
conditions  of  the  license,  if  any,  the  opponent  is 
prepared  to  grant  to  the  applicant  and  shall  be 
accompanied by evidence in support of the opposition 
[Rule 98(2)]. The opponent shall serve a copy of his 
notice  of  opposition  and  evidence  on  the  applicant 
and notify the Controller when such service has been 
effected [Rule 98(3)]. The Controller shall forthwith 
fix a date and time for the hearing of the case and 
shall give the parties no less than 10 days notice of 
such hearing [Rule 98(5)]. The procedure specified in 
Rule  62(2)-(5),  shall  apply  to  the  procedure  for 
hearing [Rule 98(6)]  
 
In setting the terms and conditions of the CL, the controller shall endeavour to secure: royalty and 
other  remuneration  reserved  to  the  patentee  /other  person  beneficially  entitled  to  the  patent,  is 
reasonable, having regard to the nature of the invention/expenditure incurred in making the invention 
and obtaining a patent/keeping it in force/relevant factors; patented invention is worked to the fullest 
extent by the person to whom the license is granted, and with reasonable profit to him; patented articles 
are made available to the public at reasonably affordable prices; license is non-exclusive; right of the 
licensee  is  non-assignable;  license  is  for  the  balance  term  of  the  patent  unless  a  shorter  term  is 
consistent with public interest; (that the license is granted with a predominant purpose of supplying in 
the  Indian  market-omitted  under  the  2005  Act),  provided,  that  the  licensee  may  also  export  the 
patented product in accordance with S. 92A, provided further that in case the license is granted to 
remedy a practice determined after judicial and administrative process to be anti-competitive, the 
licensee  shall  be  permitted  to  export  the  patented  product-omitted  under  the  2005  Act)  [2004 
Ordinance] that the license is granted with the predominant purpose of supply in the Indian market 
and that the licensee may also export the patented product if need be, that in case the license is 
granted to remedy a practice determined after judicial/administrative process to be anti-competitive, 
the licensee shall be permitted to export the patented product , S. 90(1). No license granted by the 
controller shall authorize the licensee to import the patented article/ article or substance made by a 
patented process where such importation would constitute an infringement of the rights of the patentee, 
S. 90(2), however, the central government may, if it is necessary in its opinion for the public interest, 
direct the controller, to authorize, any licensee to import the patented article/article or substance made 
by a patented process, S. 90(3).  
If the Controller is satisfied that the manufacture/use/sale 
of materials not protected by the patent is prejudiced by 
conditions imposed by patentee on the grant of license 
under  the  patent/the  purchase/hire/use  of  the  patented 
articles/process, then he may order the grant of licenses 
under  the  patent  as  he  thinks  fit,  S.  88(1).  After  the 
sealing of the patent, any person who has the right to 
work any other patented invention either as patentee or 
licensee (exclusive or not), may apply to the controller 
for the grant of a license this patent on the ground that he 
is  hindered  or  prevented  without  such  license  from 
working  the  other  invention  efficiently  or  to  the  best 
advantage  possible  [cannot  work  patent  without 
infringing  the  other  or  this  patent  involves  important 
technological  advancements  or  considerable  economic 
significance in relation to the other patent, S. 88(3)], S. 
91(1). No such order shall be made, unless the controller 
is satisfied, that (i) that the applicant is able and 
willing to grant, or procure the grant to the 
patentee  or  his  licensees,  of  a  license  in 
respect of the other invention on reasonable 
terms,  (ii)  that  the  other  invention  has  made  a 
substantial  contribution  to  the  establishment  or 
development  of  commercial/industrial  activities  in  the 
territory of India. Controller may order on the terms he 
thinks fit the license, “further the license granted by the 
controller  shall  be  non-assignable  except  with  the 
assignment  of  the  respective  rights”  [2002 
Amendment], S. 91(3). The provisions of Sections 87, 
88, 89 and 90 shall apply to licenses granted under this 
section, S. 91(4).  
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If the Controller is satisfied that a prima facie case has not been made 
out for the revision of the terms and condition of the license, he may 
notify  the  applicant  accordingly  and  unless  within  a  month  of  the 
applicant requests to be heard in the matter, the Controller may refuse 
the application. If the Controller allows the application to be proceed 
with, he shall direct the applicant to serve copies of the application and 
of the evidence in support thereof upon the patentee or any other person 
appearing in the register to be interested in the patent or upon any other 
person on whom, in his opinion such copies should be served [Rule 
101(1)].  The  patentee  or  any  other  person  on  whom  copies  of  the 
application  and  of  the  evidence  has  been  served,  may  give  to  the 
Controller notice of the opposition within 1 month from the date of such 
service.  Such  notice  shall  contain  the  grounds  relied  upon  by  the 
opponent  and  shall  be  accompanied  by  evidence  in  support  of  the 
opposition [Rule 100(3)]. On completion of the above proceedings, the 
Controller shall forthwith fix a date and the time for the hearing of the 
case  and  shall  give  the  parties  not  less  than  10  days  notice  of  such 
hearing [Rule 100(6)]. The procedure in Rule 62(2)-(5) shall, so far as 
may apply to the procedure for hearing under this rule as they apply to 
the hearing of opposition to the grant of patent [Rule 100(7)] 
 
Where the terms and conditions of a license have been settled by the 
controller,  the  licensee  may,  at  any  time  after  he  has  worked  the 
invention on a commercial scale for a period not less than 12 months, 
make an application to the controller for the revisions of the terms and 
condition on the grounds that the terms and conditions have proved more 
onerous and that the licensee is unable to work the invention, except at a 
loss, S. 88(4). 
SPECIAL  PROVISIONS  FOR  CL  ON  NOTIFICATIONS  BY  THE  CENTRAL 
GOVERNMENT: If the Central Government is satisfied, in respect of a patent in force in 
circumstances of national emergency, extreme urgency or public non-commercial use, that it 
is  necessary  that  CL  should  be  granted  after  the  sealing  to  work  the  invention,  then 
Controller shall grant license to a person interested on terms and conditions as he thinks fit 
[here, “notwithstanding Section 90(2), where the Controller is satisfied that it is necessary in 
a  circumstance  of  national  emergency/extreme  urgency/public  non-commercial  use 
including  public  health  crisis,  related  to  AIDS,  human    immuno  deficiency  virus, 
tuberculoses,  malaria  or  other  epidemics”,[2002  Amendment],  S.  87  will  not  apply,  S. 
92(3)], endeavouring to secure that the articles manufactured under the patent be available to 
the public at the lowest price consistent with the patentees deriving a reasonable advantage 
from their patent rights, S. 92(1). Sections 83, 87, 88, 89 and 90 shall apply, S. 90(2). 
Section  92A-(1)  CL  should  be  available  for  manufacture  and  export  of  patented 
pharmaceutical products to any country having insufficient or no manufacturing capacity 
in the pharmaceutical sector for the concerned product to address public health problems, 
provided CL’s have been granted by such countries or such country has by notification or 
otherwise allowed importation of the patented pharmaceutical product from India, (2) the 
controller shall, on receipt of an application in the prescribed manner, grant a CL solely 
for manufacture and export of the concerned pharmaceutical product to such country 
under such terms and conditions as may be specified and published by him, (3) (1) and (2) 
shall be without prejudice to the extent to which pharmaceutical products produced under 
a CL can be exported under any provisions of this Act. For the purpose of this section, 
‘pharma  products’  means  any  patented  product,  or  product  manufactured  through  a 
patented process, of the pharma sector needed to address public health problems and shall 
be inclusive of ingredients necessary for their manufacture and diagnostic kits required 
for their use [2004 Ordinance] 
 
On an application by the patentee or any other person deriving 
an interest/title in the patent, a CL may be terminated by the 
controller  [The  application  shall  be  accompanied  by  the 
evidence in support of the application [Rule 102(1)]], if and 
when circumstances that gave rise to the grant no longer exist 
and such circumstances are unlikely to reoccur, S. 94. The 
applicant shall serve a copy of the application and evidence on 
the  holder  of  the  compulsory  license  and  shall  inform  the 
Controller  the  date  on  which the  service  has been  effected 
[Rule 102(2)]. The holder of the Compulsory License may file 
his  objection  along  with  the  evidence,  if  any,  to  the 
application within 1 month from the date of receipt of the 
application and evidence by him to the Controller and serve a 
copy thereof to the applicant [Rule 102(3)]. On completion of 
the above proceedings, the Controller shall forthwith fix a date 
and the time for the hearing of the case and shall give the 
parties  not  less  than  10 days  notice  of  such hearing [Rule 
100(5)]. The procedure specified in sub-rules Rule 62 (2)-(5) 
so far as may be, apply to the procedure for hearing under this 
rule as they apply to the hearing of opposition to the grant of 
patent [Rule 100(6)]. “The controller shall take into account 
that the interest of the person granted the CL is not unduly 
prejudiced”  [2002  amendment],  S.  94.  In  the  Controller 
decides  to  terminate  the  Compulsory  License  he  shall 
forthwith issue an order giving terms and conditions, if any, of 
such termination  and  serve  copies  of  the  order  to  both the 
parties [Rule 100 (7)] 
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2.5.2.  Patenting Procedure 
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Application for Patent (not being 
a  convention  application  or  an 
application filed under the PCT  
designating  India)  S.  9(1)  + 
Provisional Specification, S.7(4)  
Abandoned, S. 9(1)  
File Complete Specification, S. 9(1).  
Every  Complete  specification  shall  (a)  fully  and  particularly 
describe the invention and its operation or use and the method by 
which  it  is  to  be  performed,  (b)  disclose  the  best  method  of 
performing the invention which is known to the applicant and for 
which he is entitled to claim protection, and (c) end with a claim 
or claims defining the scope of the invention for which protection 
is claimed, S. 10(4).  
Where applications for inventions are cognate or where one is a 
modification of another the Controller may deem them a single 
invention and allow one complete specification to be filed for all 
provisional specifications provided that the time period shall be 
reckoned  from  the  date  of  filing  of  the  earliest  provisional 
specification, S. 9(2).  
Where an application for a patent is accompanied by a complete 
specification the Controller may within 12 months from the date 
of  filing  of  the  application  that  such  specification  shall  be 
treated as provisional, if the applicant so request, S. 9(3). 
The Controller may on the request of the applicant at any time 
before the grant of the patent, cancel the provisional specification 
and post –date the application to a date no later than 6 months 
from  the  date  on  which  the  application  was  made,  (S.  17(1)) 
subject to the date of filing the complete specification, S. 9(4).  
If the applicant mentions a biological material in the specification 
which may not fully and particularly describe the invention and its 
operation or use and the method by which it is to be performed or 
which may not fully disclose the best method for performing the 
invention  known  to  the  applicant,  and  if  such  material  is  not 
available  to  the  public,  the  application  shall  be  completed  by 
depositing the material to an international depository authority 
under the Budapest Treaty, S. 10(4)(d)(ii) and by fulfilling the 
following conditions: 
￿  A deposit of the material shall be made no later than the 
date  of  filing  the  patent  application  in  India  and  a 
reference  shall  be  made  in  the  specification    3  months 
from such filing, Rule 13(8) S. 10(4)(d)(ii)(A)  
￿  On publication of an application the depository institution 
shall  make  the  biological  material  mentioned  in  the 
complete specification available publicly (S. 11A(6))  
￿  A disclose[ure of the] the source and geographical origin of 
the biological material in the specification [shall be made], 
when used in an invention, S. 10(4)(d)(ii)(D),  
￿  Access  to  the  material  [will  be  made]  available  in  the 
depository institution only after the date of the application 
for patent in India or if a priority is claimed after the date of 
priority, S. 10(4)(d)(ii)(C).  
￿  A complete specification may include claims in respect of 
developments of or additions to the invention which was 
described  in  the  provisional  specification,  being 
developments or additions in respect of which the applicant 
would  be  entitled  to  make  a  separate  application  for  a 
patent, S. 10(7)  
Applicant for a patent in a country outside India for the same or substantially the 
same invention, shall undertake that upto the grant of patent in India he will keep 
the Controller informed of the detailed particulars of such application + furnish 
details relating to the processing of the application in the country outside India, the 
period within which the applicant shall file the statement and undertaking shall 
be 3 months from the date of filing the application, R. 12(1A) (3 months from the 
date  on  which  application  is  filed  in  India  in  case  of  an  application 
corresponding to an international application, R. 12(1A)) and 3 months from 
date of communication by the Controller, respectively, (R. 12(3)) 
Where  a  Complete 
Specification  is  filed  in 
pursuance of a provisional 
specification and the claim 
is  fairly  disclosed  in  the 
specification,  the  priority 
date  shall  be  the  date  of 
filing  the  provisional 
specification, S. 11(2) 
Applications for patents shall not be open to the public 
for a period of 18 months from the date of filing of the 
complete specification or the date of priority whichever 
is earlier [R. 24], S. 11A (1). The applicant may request 
the  Controller  to  publish  his  application  at  any  time 
before  the  expiry  of  the  above  mentioned  period  and 
subject to secrecy direction (under a secrecy direction it 
shall be published after 18 months or when the secrecy 
direction  has  ceased  to  operate,  whichever  is  later,  S. 
11A(4))  (S.  35),  abandonment  (S.  9(1)),  withdrawn  3 
months prior to the 18 month time period, S. 11A(2).  
On and from the date of publication of the application 
and until the date of grant of the patent, the applicant 
shall have the like privileges and rights as if a patent for 
the invention has been granted on the date of publication 
of  the  application,  applicant  shall  not  be  entitled  to 
institute  any  proceedings  for  infringement  until  the 
patent  has  been  granted.  The  rights  of  a  patentee  in 
respect  of  applications  made  under  S.  5(2)  before 
1.1.2005  shall  accrue  from  the  date  of  grant  of  the 
patent,  S.  11A(7).  Provided  after  a  patent  is  granted 
under  S.  5(2),  the  patent  holder  shall  only  receive 
reasonable  royalty  from  an  enterprise  which  has  made 
significant  investment  and  was  producing/marketing  the 
product  prior  to  1.1.2005  and  which  continue  to 
manufacture on date of grant of patent + no infringement 
proceedings  
Request for examination (within 48 months from the date of filing, S. 11B(1)) of the application for 
patent, shall be made after the publication of the application but within 36 months from the date of 
priority  or  the  date  of  filing  of  the  application,  whichever  is  earlier  [R.  24B(i)].  (In  case  of  an 
application in respect of a claim for a patent filed under Section 5(2), a request for an examination shall 
be made with a period of 12 months from 31
st December, 2004 or within 48 months from the date of 
application, whichever is later, S. 11(2)) In case of an application filed under S. 5(2) before 1.1.2005 a 
request for its examination shall be made shall be 36 months from the date of priority or the date of 
filing the application or 12 months from 1
st January, 2005 [R. 24B(ii)]. In case the applicant or any 
other interested person does not make a request for examination of the application for a patent within 36 
months from the date of priority or the date of filing of the application, or within 6 months from the 
date of revocation of  the secrecy directions, whichever is later, the application shall  be treated as 
withdrawn [R. 24B(iii)]. Period for making a request for examination under S. 11B before the 1
st of 
January, 2005 shall be 36 months or the period specified under any of the above rules, whichever 
expires later [R. 24(1)(B)(v)] 
When  a  request  for    examination  has  been  made  in 
respect of an application for a patent, the application 
shall be referred to the Examiner at the earliest, by the 
Controller for making a report to him in (18 months, S. 
12(2)) ordinarily one month but not exceeding three 
months from the date of reference of the application 
to him by the controller [R. 24B(2)(ii)], in respect of 
the following matters: (a) whether the application and 
the specification and other documents relating thereto 
are in requirement of this Act and of any rules made 
thereunder, (b) whether there is any lawful ground of 
objection to the grant of the patent under this Act in 
pursuance of the application, (c) search for anticipation 
by previous publication and by prior claim (S. 13), and 
(d) any other matter that may be prescribed. S. 12(2).  
A  first  examination report  along  with 
the application and specification shall 
be sent to the applicant, his authorized 
agent  or  any  other  interested  person 
who files a request for examination [R. 
24B(3)]  
An applicant shall submit his first reply 
to the first examination report within a 
period  of  4  months  from  the  date  of 
issue of such statement [R. 24(4)] 
Priority under the Patent 
Co-operation [PCT] treaty 
and the Paris Convention 
31 months from 
priority date [R. 
20(4)(i)]. Patent 
office will on 
express request 
examine before 
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On receipt of the notice of opposition, the controller shall by order constitute an opposition board and it shall submit a report with recommendations three 
months from the date on which the documents were forwarded to them [Rule 56] 
 
On receiving the notice, the applicant shall, if he so desires, files his statement and evidence, if any in support of his application within one month from 
the date of notice [Rule 55(4)] 
 
On consideration of the statement and evidence filed by the applicant, the controller may refuse to grant a patent on the application or require the 
complete specification to be amended to his satisfaction before the grant of the patent [Rule 55(5)] 
 
After considering the representation and submission made during the hearing if so requested, the controller shall proceed further simultaneously either 
rejecting the representation and granting the patent or accepting the representation and refusing the grant of the patent on that application, ordinarily 
within one month from the completion of the above proceedings [Rule 55(6)] 
 
Opposition to grant of patent: (at any time within 4 months from the date of advertisement of acceptance of complete specification (+1 month)) Where an 
application for a patent has been published but a patent has not been granted, any person may, in writing, represent by way of opposition to the 
Controller against the grant of the patent on the ground of:  (a) patentability including novelty, inventive step and industrial applicability, or (b) non-
disclosure or wrongful mentioning in complete specification, source and geographical origin of biological material used in the invention and anticipation 
of invention by the knowledge, oral or otherwise available within any local or indigenous community in India or elsewhere, or (c) that the patentee or the 
person under/through whom he claims wrongfully obtained the invention or any part thereof from him or from a person under/through whom he claims,  (d) 
that the invention so far as claimed in any claim of complete specification has been published before the priority date of the claim in any specification filed in 
pursuance of an application for a patent made in India on or after 1
st January, 1912, in India or elsewhere in any document, (e) that the invention is claimed 
in a complete specification published on or after the priority date of the claim of the patentee and filed in pursuance of an application for a patent in India, 
being a claim of which the priority date is earlier than that of the claim of the patentee, (f) that the invention claimed in the complete specification was 
publicly known or used in India before the priority date of that claim (here, an invention relating to a process for which a patent is granted shall be deemed 
to have been publicly known or publicly used in India before the priority date of a claim if the product made by that process had already been imported into 
India before that date except where such importation has been for the purpose of reasonable trial or experiment only), (g) that the invention claimed is 
obvious and does not involve an inventive step, having regard to (b) or having regard to what was used in India before the priority date of the claim, (h) that 
the subject of any claim of complete specification is not an invention or not patentable, (i) that the complete specification does not sufficiently and clearly 
describe the invention or the method by which it is to be performed, (j) that the patentee has failed to disclose to the Controller the information required by S. 
8 or has furnished information which in any material particular was false to his knowledge, (k) that in the case of a patent granted on convention 
application, the application for the patent was not made within 12 months from the date of the first application for protection for the invention made in a 
convention country or in India, (l) that the complete specification does not disclose or wrongly mentions the source and geographical origin of biological 
material used for the invention, (m) that the invention so far claimed in any claim of complete specification was anticipated having regard to the knowledge, 
oral or otherwise, available within any local or indigenous community in India or elsewhere, S. 25(1). The Controller shall if requested by such persons for 
being heard, hear him and dispose of the representation in such manner and within such period as may be prescribed. (A person making a representation 
shall not be made party to any proceeding under this Act only for the reason that he has made such representation, S. 25(2)) 
Opposition by representation: Representation for opposition shall be filed within a period not exceeding (within 4 months from the date of advertisement of 
the acceptance of the complete specification, R. 56(1)) six three months from the date of publication of the application under 11A, or before the grant of 
patent, whichever is later, and shall include a statement and evidence, if any, in support of the representation and a request for hearing if so desired [Rule 
55 (1)] 
Filing of written statement of opposition and evidence: The opponent shall send a written statement setting out the nature of the opponent’s interest, the 
facts upon which he bases his case and relief which he seeks and evidence, if any, along with notice of opposition (or within 2 months from the date of the 
notice of opposition) and shall deliver to the applicant a copy of the statement and the evidenced [Rule 57] 
 
If the (applicant) patentee desires to contest the opposition, he shall leave at the appropriate office a reply statement setting out fully the grounds upon 
which the opposition is contested and evidence, if any by him under Rule 57 and delivery to the opponent a copy thereof [Rule 58(1)]. If the applicant does 
not desire to contest or leave his reply and evidence within the period as specified in sub-rule (1), the shall be deemed to have been revoked [Rule 58(2)] 
The opponent may, within 1 month from the date of delivery to him of a copy of the (applicant’s) patentees reply statement and evidence under Rule 58, 
leave at the appropriate office evidence in reply strictly confined to matters in the applicants evidence and shall deliver to the applicant a copy of such 
evidence [Rule 59] 
 
No further evidence shall be delivered by either party except with the leave or the direction of the Controller, provided that such leave or direction is 
prayed before the controller has fixed the hearing under Rule 62 [Rule 60] 
 
On the completion of the presentation of evidence or on receiving the recommendation of the Opposition Board or at any other time as the Controller may 
think fit, he shall forthwith fix a date and time for the hearing of the opposition and shall give the parties not less than 10 days notice of such hearing 
[Rule 62(1)] If either party to the proceeding desires to be heard, he shall inform the controller by notice [Rule 62(2)] The Controller may refuse to hear 
any party who has not given notice [Rule 62(3)]. After hearing the party or parties desirous of being heard, or if neither party desires to be heard, then 
without a hearing, and after taking into consideration the recommendation of the opposition board, the Controller shall forthwith decide the opposition 
and notify his decision to the parties giving reasons thereof [Rule 62(4)]   28 














Request for examination 
Is  claimed  in  any  other  complete  specification 
published on or after the date of filing of the complete 
specification,  dated  before  or  claiming  the  priority 
date earlier than that date, S. 13(1)(b).  
 
The  examiner  shall  investigate  whether  the 
invention in a complete specification, S. 13 
  
If  the  controller  is  satisfied  that  the 
invention  claimed  in  the  complete 
specification has been anticipated then the 
Controller shall communicate the gist of 
specific objections to the applicant and the 
applicant shall be afford an opportunity to 
amend his specification [R. 28(1)]  
Application  deemed  to  be  abandoned,  unless,  (12 
months)  6  months  (+  3  months  in  circumstances 
beyond the control of the applicant, R. 24B(4)(ii)) 
[R.  24B(4)(i)]  from  when  the  first  statement  of 
objection is forwarded to the applicant the applicant 
has complied with all the requirements imposed in 
connection  with  the  complete  specification  or  the 
application,  S.  21(1).  The  time  for  putting,  all  the 
applications in order for acceptance which have been 
examined before the commencement of the Patents 
(Amendment) Act, 2002, shall be 15 months or 18 
months as the case may be, from the date on which 
the  first  statement  of  objections  is  issued  to  the 
applicant to comply with the requirements [R. 24(5)]. 
Where  the  application  for  a  patent  or  any 
specification  or,  in  the  case  of  a  convention 
application  or  an  application  filed  under  the  PCT 
designating India, any document filed as part of the 
application has been returned to the applicant by the 
Controller, the applicant shall not be deemed to have 
complied with such requirements unless he has re-
filed it or the applicant proves to the satisfaction of 
the  controller  that  for  reasons  beyond  his  control 
such document could not be re-filed. Except if at the 
end  of  (12  months)  6  months  (+  3  months  in 
circumstances beyond the control of the applicant, 
R.  24B(4)(ii))  [R.  24B(4)(i)]  an  appeal  to  the 
(Appellate Board) High Court is pending in respect 
of  the  application  for  the  patent  for  the  main 
invention, or in the case of an application for a patent 
of addition, an appeal to the (Appellate Board) High 
Court is pending in respect of either that application 
or the application for the main invention, then time 
for compliance shall be extended until such date as 
the (Appellate Board) High Court may determine, S. 
21(3) [S. 21(2)]. If the time within which the appeal 
mentioned  in  (3)  [(2)]  may  be  instituted  has  not 
expired, the controller may extend  the period under 
(1)  to  such  further  time  (12  months) as may be 
determined:  provided that  if an appeal has  been 
filed  during  the  said  further  period,  and  the  (High 
Court) Appellate Board has granted any extension of 
time  for  complying  with  the  requirements  of  the 
controller,  then  the  requirements  may  be  complied 
within  the  time  granted  by  the  (Appellate  Board) 
High Court, [S. 21(3)] 
 
When it is found that the invention 
claimed  in  any  claim  of  the 
complete specification, is claimed in 
any other specification, the applicant 
shall  be  so  informed  and  shall  be 
afforded  an  opportunity  to  amend 
his specification [R. 29(1)] 
The examiner shall investigate whether 
the  invention  in  a  complete 
specification, S. 13 
 
Controller may refuse the application, unless 
the applicant: (1) shows to the satisfaction of 
the  Controller  that  the  priority  date  of  the 
claim  of  the  complete  specification  is  no 
later  than  the  date  on  which  the  relevant 
document was published, or (2) amends his 
complete specification to the satisfaction of 
the controller (see Section’s 57 and 59), S. 
18(1). 
Exceptions:  An  invention  claimed  in  a 
complete  specification  is  not  anticipated 
where:  an  invention  is  published  in  a 
specification  for  a  patent  made  in  India 
before the 1
st of January, 1912 (S. 29(1)), an 
invention  is  published  before  the  priority 
date of the specification, but patentee proves 
(i)  that  the  matter  published  was  obtained 
from  him/from  any  person  from  whom  he 
derives  title/published  without  (their) 
consent (S. 29(2)(a)), (ii) the patentee or any 
person from whom he derives title learned 
of  the  publication  before  the  date  of  the 
application  for  the  patent  in  India  or  a 
Convention Country and the application in 
India or the convention country was made as 
soon  as  reasonable  practicable  thereafter 
[not  applicable  if  the  invention  was  made 
before  the  priority  date  of  the  claim 
commercially  worked  in  India,  except  for 
the purpose of reasonable trial with consent 
from the patentee or from whom he derives 
title] (S. 29(2)(b)), an invention claimed in a 
complete specification is not anticipated by 
reason of any other application for a patent 
in  respect  of  the  same  invention  made  in 
contravention of the rights of the true and 
first  inventor  or person deriving title from 
him, or by reason that after the date of filing 
of that other application the invention was 
used or published, without the consent of the 
person,  by  the  applicant  in  respect  of  the 
other application, or by any other person in 
consequence  of  any  disclosure  of  any 
invention by that applicant, S. 29(3) 
Exceptions:  Invention  claimed  in  a  complete 
specification  shall  not  be  deemed  to  have  been 
anticipated  by  communication  of  the  invention to  the 
government  or  any  other  person,  authorized  by  the 
government to investigate the invention or its merits, or 
of  anything  done,  in  consequence  of  such  a 
communication, for the purpose of the investigation, S. 
30 
No anticipation by public display if the application for 
the  patent  is  made  by  the  true  and  first  inventor  or 
person deriving title from him no later than (six) twelve 
months after the opening of the exhibition or the reading 
of the paper S. 31.  
Invention  claimed  in  a  complete  specification  not 
anticipated  by  reason  that  within  1  year  before  the 
priority date of the relevant claim of the specification, 
the invention was publicly worked in India, (a) by the 
patentee or applicant for the patent or any person from 
whom he derives title, or (b) by any other person with 
the consent of the patentee or applicant for the patent or 
any person from whom he derives title, if the working 
was effected for the purpose of reasonable trial only and 
if  it  was  reasonably  necessary,  having  regard  to  the 
nature  of  the  invention,  that  the  working  for  that 
purpose should be effected in public, S. 32.  
Where  a  complete  specification  is  filed  or  proceeded 
with  in  pursuance  of  an  application  which  was 
accompanied  by  a  provisional  specification/treated  as 
provisional  specification  under  S.  9(3),  then  the 
Controller shall not refuse to grant the patent, and the 
patent shall not be revoked or invalidated, by reason that 
any  matter  described  in  the  provisional  specification 
was used in India or published in India or elsewhere at 
any  time  after  the  date  of  filing  the  specification,  S. 
33(1);  Where  a  complete  specification  is  filed  in 
pursuance of a convention application then, the patent 
shall not be revoked or invalidated, by reason that any 
matter disclosed in any application for protection in a 
convention  country  upon  which  the  convention 
application is founded was used in India or published in 
India  or  elsewhere  at  any  time  after  the  date  of  the 
application for protection, S. 33(2) 
[Omitted  by  the  2004  Ordinance]  Acceptance: 
The  applicant  may  make  an  application  to  the 
controller requesting him to postpone acceptance 
until such date, not being later than 12 months 
from  the  date  on  which  the  objections  were 
referred  to  the  applicant,  S.  22.  The  controller 
shall  give  notice  to  the  applicant  and  shall 
advertise the fact that the specification has been 
accepted and thereafter the specification shall be 
open to public inspection, S. 23. On and from the 
date  of  advertisement  of  the  acceptance  of 
complete  specification  and  until  the  date  of 
sealing of a patent, the applicant shall have the 
like  privileges  and  rights  as if  a  patent  for  the 
invention  has  been  sealed  on  the  date  of 
advertisement  of  acceptance  of  complete 
specification, provided that the applicant shall not 
be  entitled  to  institute  any  proceedings  for 
infringement until the patent has been sealed, S. 
24. After acceptance and before grant if it comes 
to the notice of controller otherwise than under S. 
25, that the application has been published before 
priority date the Controller may refuse to grant 
patent  unless  the  complete  specification  is 













































If the applicant requests for a hearing 
under Rule 28(2) within a period of 1 
month from the date of communication 
of  the  gist  of  the  objection,  or,  the 
controller, considers it desirable to do 
so, whether or not the applicant has re-
filed his application, he shall fix a date 
and time for hearing having regard to 
the  period  remaining  for  putting  the 
application  in  order  or  to  the  other 
circumstances of the case [Rule 28(3)] 
 
If  the  applicant  contests  any  of  the 
objections communicated to him by the 
Controller,  or  if  he  re-files  his 
specification  along  with  his 
observations as to  whether  or not  the 
specification is to be amended, he shall 
be given an opportunity to be heard in 
the  matter  if  he  so  requests  (such 
request shall be made on a date earlier 
than 10 days of the final date referred 
to under Section 21(1)) and a request 
for hearing may be allowed to be filed 
within  such  shorter  period  as  the 
Controller  may  deem  fit  in  the 
circumstances of the case [R. 28(2)] 
The  applicant  shall  be  given  10  days 
notice  of  any  such  hearing  or  such 
shorter  notice  as  appears  to  the 
Controller  to  be  reasonable  in  the 
circumstances  of  the  case  and  the 
applicant  shall,  as  soon  as  possible, 
notify  the  controller  whether  he  will 
attend the hearing [Rule 28(4)] 
 
After hearing the applicant, or without 
a  hearing  if  the  applicant  has  not 
attended or has notified that he does not 
desire to be heard, the Controller may 
specify  or  permit such  amendment  of 
the specification as he thinks fit to be 
made  and  may  refuse  to  grant  the 
patent  unless  the  amendment  so 
specified  or permitted is made  within 
such  period  as  may  be  fixed  [Rule 
28(5)] 
 
If  the  applicants  specification  is 
otherwise  than  for  order  for grant 
and  an  objection  under  Section 
13(1)(b)  is  outstanding,  the 
Controller  may  postpone  the  grant 
of  patent  and  allow  a  period  of  2 
months to remove the objection [R. 
29(2)] 
If  the  applicant  so  requests  at  any 
time or if the Controller is satisfied 
that  the  objection  has  not  been 
removed within the period referred 
to in Rule 29(2), a date for hearing 
the applicant shall be fixed forthwith 
and the applicant shall be given at 
least 10 days notice of the date so 
fixed. The applicant shall, as soon as 
possible,  notify  the  Controller 
whether  he  will  attend  the  hearing 
[Rule 30(1)] 
After  hearing  the  applicant  or 
without  a  hearing  if  the  applicant 
has not attended or has notified that 
he does not desire to be heard, the 
Controller  may  specify  or  permit 
such amendment of the specification 
as  will  be to his satisfaction  to be 
made and may direct that reference 
to  such  other  specification,  as  he 
shall mention shall be inserted in the 
applicant’s  specification  unless  the 
amendment  is  made  or  agreed  to 
within such period as may be fixed 
[Rule 30(2)]   30 
 











Grant of the Patent: Where a an application for a patent has been 
(accepted)  found  in  order  for  grant  of  patent  and,  ((a)  the 
application has not been opposed under S. 25 and the time for the 
filing of the opposition has expired) [omitted, 2004 Ordinance]; 
or ((b) the application has been opposed and the opposition has 
been  finally  decided  in  favor  of  the  applicant)  [omitted,  2004 
Ordinance]; or (c) the application has not been refused by the 
Controller  by  virtue  of  any  power  vested  in  him,  or  (d)  the 
application has not been found to be in contravention of any of the 
provisions  of  the  Act,  the patent shall  on  request made by  the 
applicant be granted, S. 43(1).  
 
A request under this section for the sealing of a patent shall be 
made no later than 6 months from the date of advertisement of the 
acceptance of complete specification, subject to exceptions (S. 
43(2)) [Omitted, 2004 Ordinance]. 
On the grant of a patent, the Controller shall publish the fact 
that the patent has been granted and thereupon the application, 
specification and other documents related thereto shall be open 
to public inspection, S. 43(2) 
A patent shall cease to have effect on the expiration of the period 
prescribed for the payment of any renewal fee, if that fee is not 
paid at the end of the second year from the date of the patent or of 
any succeeding year, R. 80(1). The period for payment of renewal 
fee shall be extended not to more than 6 months if request made 
[Rule 80(1A)]. Where a principal patent is granted later than 2 
years from the date of filing of the application, the fees may be 
paid within a term of 3 months from the date of recording of the 
patent in the register (+ not later than 9 months from the date of 
recording), S. 142(2) 
Every patent shall be dated as of the date on which the application 
for patent was filed, S. 45. No suit or other proceeding shall be 
commenced  or  prosecuted  in  respect  of  an  infringement 
committed before the date of (advertisement of the acceptance of 
the  complete  specification)  publication  of  the  application, 
S.45(3). Term of patent is 20 years from filing of the application, 
S.  53(1).  Explanation-the  term  of  a  patent  in  case  of 
international  application  filed  under  PCT  designating  India, 
shall  be  20  years  from  the  international  filing  date  accorded 
under the PCT.  
Where a patent has ceased to have effect by reason of failure to 
pay any renewal fees, then the patentee may within 18 months 
from the date on which the patent ceased to have effect, make an 
application for the restoration of the patent, S. 60(1) 
Where  the  Controller  is 
satisfied  that  a  prima  facie 
case for the restoration of any 
patent has not been made out 
(that is, failure to pay the fee 
was  unintentional  and  there 
has  been  no  undue  delay  in 
making  the  application,  S. 
61(1)),  he  shall  intimate  the 
applicant  accordingly  and 
unless  the  applicant  makes  a 
request  to  be  heard  in  the 
matter  within  1  month  from 
the date of such intimation the 
Controller  shall  refuse  such 

































Where the applicant requests for a hearing within the time allowed and 
the Controller, after giving the applicant such a hearing, is prima facie 
satisfied that the failure to pay the renewal fees was unintentional, he 
shall  (advertise)  publish  the  application  in  the  Official  Gazette  [R. 
84(3)] 
 
Opposition to restoration at any time within 2 months from the date of 
(advertisement) publication of the application in the Official Gazette 
[R.  85(1)].  The  procedure  specified  in  Rules  57  to  62,  apply  to  the 
hearing of the opposition [R. 84(3)]  
 
Where the Controller decides in favour of the applicant, the applicant 
shall  pay  the  unpaid  renewal  fees  and  the  additional  fees,  within  1 
month  from  the  date  of  the  order  of  the  Controller  allowing  the 
application for restoration [Rule 86(1)] 
 
Opposition to grant of patent:  
At any time after the grant but before the expiry of a 
period  of  one  year  from  the  date  of  publication  of 
grant of patent, any person interested may give notice 
of  opposition  to  the  Controller  on  the  following 
grounds, S. 25(3):  
(a)  that  the  patentee  or  the  person  under/through 
whom he claims wrongfully obtained the invention or 
any  part  thereof  from  him  or  from  a  person 
under/through whom he claims,  
(b) that the invention so far as claimed in any claim of 
complete specification has been published before the 
priority date of the claim in any specification filed in 
pursuance  of  an  application  for  a  patent  made  in 
India  on  or  after  1
st  January,  1912,  in  India  or 
elsewhere in any document,  
(c)  that  the  invention  is  claimed  in  a  complete 
specification published on or after the priority date of 
the claim of the patentee and filed in pursuance of an 
application  for  a  patent  in  India,  being  a  claim  of 
which the priority date is earlier than that of the claim 
of the patentee,  
(d)  that  the  invention  claimed  in  the  complete 
specification  was  publicly  known  or  used  in  India 
before  the  priority  date  of  that  claim  (here,  an 
invention relating to a process for which a patent is 
granted shall be deemed to have been publicly known 
or publicly used in India before the priority date of a 
claim if the product made by that process had already 
been  imported  into  India  before  that  date  except 
where such importation has been for the purpose of 
reasonable trial or experiment only),  
(e) that the invention claimed is obvious and does not 
involve  an  inventive  step,  having  regard  to  (b)  or 
having regard to what was used in India before the 
priority date of the claim,  
(f)  that  the  subject  of  any  claim  of  complete 
specification is not an invention or not patentable,  
(g)  that  the  complete  specification  does  not 
sufficiently and clearly describe the invention or the 
method by which it is to be performed,  
(h)  that  the  patentee  has  failed  to  disclose  to  the 
Controller  the  information  required  by  S.  8  or  has 
furnished  information  which  in  any  material 
particular was false to his knowledge,  
(i) that in the case of a patent granted on convention 
application,  the  application  for  the  patent  was  not 
made  within  12  months  from  the  date  of  the  first 
application for protection for the invention made in a 
convention country or in India,  
(j) that the complete specification does not disclose or 
wrongly mentions the source and geographical origin 
of biological material used for the invention,  
(k) that the invention so far claimed in any claim of 
complete specification was anticipated having regard 
to the knowledge, oral or otherwise, available within 
any  local  or  indigenous  community  in  India  or 
elsewhere. 
Opposition  by  representation:  Representation  for  opposition  shall  be 
filed within a period not exceeding (within 4 months from the date of 
advertisement of the acceptance of the complete specification, R. 56(1)) 
six three months from the date of publication of the application under 
11A,  or  before  the  grant  of  patent,  whichever  is  later,  and  shall 
include  a  statement  and  evidence,  if  any,  in  support  of  the 
representation and a request for hearing if so desired [Rule 55 (1)].  
 
On receipt of the notice of opposition, the controller shall by order 
constitute  an  opposition  board  and  it  shall  submit  a  report  with 
recommendations three months from the date on which the documents 
were forwarded to them [Rule 56] 
 
On receiving the notice, the applicant shall, if he so desires, files his 
statement and evidence, if any in support of his application within one 
month from the date of notice [Rule 55(4)] 
 
On consideration of the statement and evidence filed by the applicant, 
the  controller  may  refuse  to  grant  a  patent  on  the  application  or 
require the complete specification to be amended to his satisfaction 
before the grant of the patent [Rule 55(5)] 
 
 
After considering the representation and submission made during the 
hearing  if  so  requested,  the  controller  shall  proceed  further 
simultaneously  either  rejecting  the  representation  and  granting  the 
patent or accepting the representation and refusing the grant of the 
patent  on  that  application,  ordinarily  within  one  month  from  the 
completion of the above proceedings [Rule 55(6)] 
 
 
Filing of written statement of opposition and evidence: The opponent 
shall send a written statement setting out the nature of the opponent’s 
interest, the facts upon which he bases his case and relief which he seeks 
and  evidence,  if  any,  along  with  notice  of  opposition  (or  within  2 
months from the date of the notice of opposition) and shall deliver to the 
applicant a copy of the statement and the evidenced [Rule 57] 



























Revocation of Patents:  
(1) A patent may be revoked on a petition of any person interested or of the Central Government by the Appellate Board (S, 
117D(1)) or on a counter claim in a suit for infringement of the patent by the High Court on any of the following grounds, that 
is to say, S. 64(1):  
(a) that the invention, so far as claimed in any claim of the complete specification, was claimed in a valid claim of earlier 
priority date contained in the complete specification of another patent granted in India;  
(b) that the patent was granted on the application of a person not entitled under the provisions of this Act to apply therefore (an 
application for a patent may be made by any of the following persons, that is to say (a) by any person claiming to be the true 
and first inventor, (b) by any person being the assignee of the person claiming to be the true and first inventor, (c) by the legal 
representative of any deceased person who immediately before his death was entitled to make such an application, S. 6);  
(c) that the patent was obtained wrongfully in contravention of the rights of the petitioner or any person under or through whom 
he claims;  
(d) that the subject of any claim of the complete specification is not an invention within the meaning of this Act;  
(e) that the invention so far as claimed in any claim of the complete specification is not new, having regard to what was publicly 
known or publicly used in India before the priority date of the claim or to what was published in India or elsewhere in any of 
the documents referred to in section 13 [no account shall be taken of personal document or secret trial or secret use and (ii) 
where the patent is for a process or for a product as made by a process, the importation of the product into India made abroad by 
the process shall constitute knowledge or use in India of the invention on the date of the importation, except where such 
importation has been for the purpose of reasonable trial or experiment only, S. 64(2)];  
(f) that the invention so far as claimed in any claim of the complete specification is obvious or does not involve any inventive 
step, having regard to what was publicly known or publicly used in India or what was published in India or elsewhere before 
the priority date of the claim [no account shall be taken of personal document or secret trial or secret use and (ii) where the 
patent is for a process or for a product as made by a process, the importation of the product into India made abroad by the 
process  shall  constitute  knowledge  or  use  in  India  of  the  invention  on  the  date  of  the  importation,  except  where  such 
importation has been for the purpose of reasonable trial or experiment only, S. 64(2)];  
(g) that the invention, so far as claimed in any claim of the complete specification, is not useful;  
(h) that the complete specification does not sufficiently and fairly describe the invention and the method by which it is to be 
performed, that is to say, that the description of the method or the instructions for the working of the invention as contained in 
the complete specification are not by themselves sufficient to enable a person in India possessing average skill in, and average 
knowledge of, the art to which the invention relates, to work the invention, or that it does not disclose the best method of 
performing it which was known to the applicant for the patent and for which he was entitled to claim protection;  
(i) that the scope of any claim of the complete specification is not sufficiently and clearly defined or that any claim of the 
complete specification is not fairly based on the matter disclosed in the specification;  
(j) that the patent was obtained on a false suggestion or representation;  
(k) that the subject of any claim of the complete specification is not patentable under this Act;  
(l) that the invention so far as claimed in any claim of the complete specification was secretly used in India, otherwise than as 
mentioned in sub-section (3), before the priority date of the claim [no account shall be taken of any use of the invention, (i) for 
the  purposes  of  reasonable  trial  or  experiment  only,  (ii)  be  the  government/any  person  authorized  by  the 
government/government undertaking, in consequence of the applicant for the patent or any person from whom he derives title 
having  communicated  or  disclosed  the  invention  directly  or  indirectly  to  the  government  or  person  authorized  or  to  the 
government undertaking, S. 64(3)];  
(m) that the applicant for the patent failed to disclose to the controller the information required by section 8 or has furnished 
information which in any material particular was false to his knowledge;  
(n)  that  the  applicant  contravenes  any  direction  for  secrecy  passed  under  section  35  or  made  or  caused  to  be  made  an 
application for the grant of a patent outside India in contravention of section 39 (2002Amendment));  
(o) that leave to amend the complete specification under section 57 or section 58 was obtained by fraud;  
(p) that the complete specification does not disclose or wrongly  mentions the source or geographical origin of biological 
material used for the invention;  
(q)  that  the  invention  so  far  as  claimed  in  ay  claim  of  the  complete  specification  was  anticipated  having  regard  to  the 
knowledge, oral or otherwise, available within any local or indigenous community in India or elsewhere..  
A patent may be revoked by the High Court on the petition of the Central Government, if the High Court is satisfied that the 
patentee has without reasonable cause failed to comply with the request of the Central Government to make/use/exercise the 
patented invention for the purposes of the government within the meaning of section 99 (any machine, apparatus, article in 
respect of which the patent is granted or any article made by using a process in respect of which the patent is granted, may be 
imported or made or on behalf of the government for the purpose merely of its own use; any process in respect of which the 
patent is granted may be used by or on behalf of the government for the purpose merely of its own use; any machine, apparatus 
or other article in respect of which the patent is granted, may be mad or used, and any process in respect of which the patent is 
granted or may be used, by any person, for the purpose merely of experiment or research including the imparting of instructions 
to pupils and; in the case of a patent in respect of any medicine or drug, the  medicine or drug may be imported by the 
government for the purpose merely of its own use or for distribution in nay dispensary, hospital or other medical institution 
which the central government may, having regard to the public service that such dispensary, hospital or medical institution 
renders, specify in this behalf by notification in the Official Gazette) upon reasonable terms, S. 64(4).  
Where the central government opines that a patent or the mode in which it is exercised is mischievous to the state or generally 
prejudicial to the public, it may, after giving the patentee an opportunity to be heard, make a declaration to that effect the 
official Gazette and then the patent shall be deemed revoked, S. 66 
 
￿  These grounds shall also be available as a defence in any suit for infringement of a patent, S. 107(1) 
￿  In  any  proceeding  before  the  Appellate  Court  or  the  High  Court  for  the  revocation  of  a  patent  (where  the 
application for an amendment is made after the grant of a patent and the nature of the proposed amendment is 
substantive, the application shall be published, R. 81(3)(a), any person interested in opposing the application shall 
give a notice of opposition within 3 months from the date of publication, R. 81(3)(b), Rules 57-63 shall apply), the 
Appellate Board or the High Court may, subject to S. 59 (amendment of an application, complete specification 
shall be made only by way of disclaimer, correction or amendment, amendment shall be allowed for the purpose of 
incorporating actual fact and no amendment of a complete specification shall be allowed where the amended 
specification  would  claim  or  describe  matter  not  in  substance  disclosed  or  shown  in  the  specification  before 
amendment, or the claim of the specification as amended would not fall wholly in the scope of the claim of the 
specification before the amendment) allow the patentee to amend his complete specification in such manner and 
subject to such conditions as the court thinks fit, and if, in any proceeding for revocation, the Appellate Board or 
High Court decides that the patent is invalid, it may allow the specification to be amended instead of revoking the 
patent, S. 58(1).  
 
If  the  (applicant)  patentee 
desires to contest the opposition, 
he shall leave at the appropriate 
office  a  reply  statement  setting 
out fully the grounds upon which 
the  opposition  is  contested  and 
evidence,  if  any  by  him  under 
Rule  57  and  delivery  to  the 
opponent  a  copy  thereof  [Rule 
58(1)]. If the applicant does not 
desire  to  contest  or  leave  his 
reply  and  evidence  within  the 
period  as  specified  in  sub-rule 
(1), the shall be deemed to have 
been revoked [Rule 58(2)] 
 
The  opponent  may,  within  1 
month from the date of delivery 
to  him  of  a  copy  of  the 
(applicant’s)  patentees  reply 
statement  and  evidence  under 
Rule 58, leave at the appropriate 
office  evidence in  reply  strictly 
confined  to  matters  in  the 
applicants  evidence  and  shall 
deliver to the applicant a copy of 
such evidence [Rule 59] 
No  further  evidence  shall  be 
delivered by either party except 
with the leave or the direction of 
the  Controller,  provided  that 
such leave or direction is prayed 
before  the  controller  has  fixed 
the hearing under Rule 62 [Rule 
60] 
 
On  the  completion  of  the 
presentation  of  evidence  or  on 
receiving  the  recommendation 
of  the  Opposition  Board  or  at 
any other time as the Controller 
may think fit, he shall forthwith 
fix  a  date  and  time  for  the 
hearing  of  the  opposition  and 
shall  give  the  parties  not  less 
than  10  days  notice  of  such 
hearing  [Rule  62(1)]  If  either 
party to the proceeding desires to 
be  heard,  he  shall  inform  the 
controller by notice [Rule 62(2)] 
The  Controller  may  refuse  to 
hear any party who has not given 
notice  [Rule  62(3)].  After 
hearing  the  party  or  parties 
desirous  of  being  heard,  or  if 
neither party desires to be heard, 
then without a hearing, and after 
taking  into  consideration  the 
recommendation  of  the 
opposition board, the Controller 
shall  forthwith  decide  the 
opposition  and  notify  his 
decision  to  the  parties  giving 
reasons thereof [Rule 62(4)]   33 
 
End Notes 
Article 27(3) of the TRIPS Agreement provides a choice in protecting plant varieties. Member may choose from 
patents, a sui generis system or a combination of the two. The sui generis system (translating roughly into self-
generating) means any system a country decides on, provided it grants effective plant breeders rights.
101 The Indian 
legislation has sought to balance plant breeder’s rights with farmer’s rights. The Indian Legislation is the first to 
grant formal rights to farmers in a way that their self-reliance not jeopardized.
102 The Indian Parliament enacted the 
Protection of Plant Varieties and Farmer’s Rights Act, 2001 on November 15, 2001.  
The Act aims to establish “an effective system for the protection of plant varieties, the rights of farmers and plant 
breeders, to encourage the development of new varieties of plants.” The three key aims of the Act are: (i) the 
protection of the rights of farmers for their contribution made at any time in conserving, improving and making 
available plant genetic resources for the development of new plant varieties, (ii) the protection of plant breeders 
rights to  stimulate investment for research and development, both in the public and  the private  sector, for the 
development of new plant varieties,
103 and (iii) giving effect to Article 27.3(b) of the TRIPS Agreement on plant 
variety protection.
104  
Application: Application for registration must be confined to a single variety and variety should not contain any 
gene or gene sequence involving terminator technology (S. 18(1)(c)). The applicants must provide the complete 
passport data of the parental lines from which the variety has been derived along with the geographical location in 
India from where the genetic material has been taken (S. 18(1)(h)). Breeders are to submit an affidavit that their 
variety  does  not  contain  a  Gene  Use  Restricting  Technology.  The  applicants  will  also  have  to  provide  all 
information about the contribution, if any, of any farmer, village community, institution or organization in the 
breeding, evolution or development of the variety and also information on the use of genetic material conserved by 
any tribal or rural families in its breeding S. 40(1) (S. 18(1)(d)). The above conditions will not, however, apply to 
the registration of farmers varieties (S. 18(1)). Applications from the foreign nationals will be entertained provided 
the country grants the same rights to Indian citizens in respect of registration of plant varieties (AAPA News, No.30, 
June 2003).  
Advertisement of application: After the variety has been registered, it is published in the gazette of India inviting 
claims of benefit sharing from those who have contributed genetic material for the development of the variety. 
Opposition to the registration may be made on the following grounds, (a) that the person opposing the application is 
entitled to the breeders right as against the applicant, or (b) the variety is not registrable under the act or (c) the grant 
of certificate of registration may not be in public interest or (d) that the variety may have adverse effect on the 
environment, S. 21(3)) (AAPA News, No.30, June 2003).  
Researcher’s Rights: Use of the variety for research/experimentation and for creating other varieties is permitted 
under the Act, S. 30. However, for repeated use as parental line for commercial production, permission from the 
breeder must be taken, S. 30 (AAPA News, No.30, June 2003).  
                                                 
101  ‘India’s Plant Variety Protection and Plant Breeders Act, 2001,’ Suman Sahai 
102  id 
103  Rights recognized under the legislation extend, for seed and/or propagating material of the protected variety, to: 
(i) production, (ii) selling, (iii) marketing, (iv) distribution, (v) export, (vi) import, these rights are consistent 
with those that have been provided under UPOV ‘91 
104  (1) New varieties [any new plant variety that conforms to the criteria of novelty, distinctiveness, uniformity and 
stability can be registered, S.15(1). The ‘distinctiveness, uniformity and stability’ criteria are the same as in the 
UPOV  (AAPA  News,  No.30,  June  2003)].  (2)  Essentially  derived  variety  [having  one  of  the  following 
characteristics, (a) predominantly derived from an initial variety while retaining the expression of the essential 
characteristics that result from the genotype or combination of the genotype of such initial variety, (b) any 
variety that is clearly distinguishable from initial variety, or (c) conforms to such initial variety in the expression 
of the essential characteristics that result from the genotype or combination of genotype of such initial variety, S. 
2(i) (Similar to that in UPOV 1991)] that differ from the patent variety by one or more characteristics can also be 
registered.  (3)  Extant  variety  [(i)  varieties  that  have  been  notified  under  the  Seeds  Act,  1996,  (ii)  farmers 
varieties, and (iii) varieties about which there is common knowledge, and (iv) any other variety that is in the 
public  domain],  S.  2(j),  and  (4)  Farmers  Varieties  [(i)  varieties  that  have  been  traditionally  cultivated  and 
evolved by farmers in their fields and (ii) a wild relative or landacre of a variety  about which farmers possess 
common knowledge], S. 2(l)   34 
Farmer’s Rights: a farmers who has bred or developed a new variety shall be entitled for registration and other 
protection in like manner as the breeder or a variety under this Act, S. 39(1)(i) 
A farmer who is engaged in the conservation of genetic resources of land races and wild relatives of economic plants 
and  their  improvement  through  selection  and  preservation  shall  be  entitled  in  the  right  prescribed  manner  for 
recognition and reward from the Gene Fund, provided that the material so selected and preserved has been used as 
donors of genes in varieties registrable under this Act, S. 39(1)(iii) 
The provisions of the Act do not affect the right of a farmer to save, use, exchange, sell or share his farm produce, if 
the produce relates to a variety protected under the act. S. 39(1)(iv). This is different from farmers exemptions 
granted under the UPOV, which were in the norm of ‘plant back rights,’ that is, the right to save seeds from the 
harvest to sow the next crop. The farmer is not entitled to sell ‘branded seed [any seed put in a package or any other 
container and labeled in a manner indicating that such seed is of a variety protected under the act]of a variety 
protected under this act, S. 39(1).  
Where any propagating material of a variety registered under this Act has been sold to farmers, the breeder shall 
disclose expected performance under given conditions if the seeds fail to provide the same the farmers may claim 
compensation, S. 39(2).  
Benefit-Sharing: After registration of the variety, any person or group of persons may stake a claim of ‘benefit 
sharing’ in the claimed variety by notifying the authority. after due investigation, the authority may order that a 
compensation be paid to the claimant (person/group of persons/non-governmental organizations) based on (a) the 
extant and the nature of the use of genetic material of the claimant in the development of the variety relating to 
which the benefit sharing has been claimed, and (b) the commercial utility and the demand in the market of the 
variety relating to which the benefit sharing has been claimed, the compensation shall be deposited at the gene fund, 
S. 26 (AAPA News, No.30, June 2003).  
Compulsory Licensing: after three years from the date of issue of a certificate of registration of a variety, any 
interested person may make an application alleging that reasonable requirements of the public for seeds or other 
propagating  material  of  the  variety  have  not  been  satisfied,  or  that  seeds  are  not  available  to  the  public  at  a 
reasonable price, and may pray for grant of cl, S. 47.  
Rights  of  communities:  any  person/group  of  persons  (actively  engaged  in  farming  or  not/non-governmental 
organizations), may on behalf of any village or community in India, file with the approval of the central government, 
any claim attributable to the contribution of the people of that village or local community, in the evolution of any 
variety for the purpose of staking a claim on behalf of such village or local community, compensation to be paid to 
gene fund, S. 41.  
Protection of innocent infringement: Rightly assuming that farmers may unknowingly infringe breeders’ rights since 
they  will  not  be  used  to  the  new  situation,  the  law  provides  for  protection  from  prosecution  for  innocent 
infringement, S. 42 
 
 
 
 
 